US20040053966A1 - Chemical derivatives and their application as antitelomerase agent - Google Patents
Chemical derivatives and their application as antitelomerase agent Download PDFInfo
- Publication number
- US20040053966A1 US20040053966A1 US10/658,394 US65839403A US2004053966A1 US 20040053966 A1 US20040053966 A1 US 20040053966A1 US 65839403 A US65839403 A US 65839403A US 2004053966 A1 US2004053966 A1 US 2004053966A1
- Authority
- US
- United States
- Prior art keywords
- amino
- group
- groups
- optionally substituted
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000126 substance Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 64
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 59
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 58
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 38
- -1 alkoxy radical Chemical class 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 125000004432 carbon atom Chemical group C* 0.000 claims description 26
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 108010017842 Telomerase Proteins 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 125000003277 amino group Chemical group 0.000 claims description 14
- 125000005842 heteroatom Chemical group 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 claims description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 10
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 10
- 229910052705 radium Inorganic materials 0.000 claims description 10
- 229910052701 rubidium Inorganic materials 0.000 claims description 10
- 125000003282 alkyl amino group Chemical group 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 125000004450 alkenylene group Chemical group 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000005237 alkyleneamino group Chemical group 0.000 claims description 8
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 7
- 125000004414 alkyl thio group Chemical group 0.000 claims description 7
- XEKAUTDWPYQNFU-UHFFFAOYSA-N chlorane Chemical compound Cl.Cl.Cl XEKAUTDWPYQNFU-UHFFFAOYSA-N 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- 108091081406 G-quadruplex Proteins 0.000 claims description 6
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- CKQQMPJQZXIYMJ-UHFFFAOYSA-N dihydrate;dihydrochloride Chemical compound O.O.Cl.Cl CKQQMPJQZXIYMJ-UHFFFAOYSA-N 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- IPPZMUSITOSBKH-UHFFFAOYSA-N triazine;hydrate Chemical compound [OH-].C1=CN=N[NH+]=C1 IPPZMUSITOSBKH-UHFFFAOYSA-N 0.000 claims description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- 229940123208 Biguanide Drugs 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- GEYMMMXKROUBAI-UHFFFAOYSA-N chlorane Chemical compound Cl.Cl.Cl.Cl.Cl GEYMMMXKROUBAI-UHFFFAOYSA-N 0.000 claims description 4
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 239000011630 iodine Substances 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- TUQMSSZVADYGKL-UHFFFAOYSA-N pentahydrate;trihydrochloride Chemical compound O.O.O.O.O.Cl.Cl.Cl TUQMSSZVADYGKL-UHFFFAOYSA-N 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 3
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 3
- IZCQDRVQVRENLX-UHFFFAOYSA-N dihydrate;trihydrochloride Chemical compound O.O.Cl.Cl.Cl IZCQDRVQVRENLX-UHFFFAOYSA-N 0.000 claims description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 3
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 claims description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims description 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 claims description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 2
- IOGGKWCHVBUUOR-UHFFFAOYSA-N 2-n,4-n-bis(4-methoxy-2-methylquinolin-6-yl)-6-methylsulfanyl-1,3,5-triazine-2,4-diamine Chemical compound N1=C(C)C=C(OC)C2=CC(NC=3N=C(N=C(SC)N=3)NC3=CC=C4N=C(C)C=C(C4=C3)OC)=CC=C21 IOGGKWCHVBUUOR-UHFFFAOYSA-N 0.000 claims description 2
- KVNBKXXDKUNBKG-UHFFFAOYSA-N 3-N',4-N,4-N-trimethyl-2-methylsulfanylmorpholine-3,3,4-triamine Chemical compound CSC1C(N(CCO1)N(C)C)(NC)N KVNBKXXDKUNBKG-UHFFFAOYSA-N 0.000 claims description 2
- KCLZZQTXNVPFIK-UHFFFAOYSA-N 6-n-[4-[(4-amino-2-methylquinolin-6-yl)amino]-6-methylsulfanyl-1,3,5-triazin-2-yl]-2-methylquinoline-4,6-diamine Chemical compound N1=C(C)C=C(N)C2=CC(NC=3N=C(NC=4C=C5C(N)=CC(C)=NC5=CC=4)N=C(N=3)SC)=CC=C21 KCLZZQTXNVPFIK-UHFFFAOYSA-N 0.000 claims description 2
- QKDPMXVGMJXKLC-UHFFFAOYSA-N 6-n-[4-[[4-(dimethylamino)-2-methylquinolin-6-yl]amino]-6-methylsulfanyl-1,3,5-triazin-2-yl]-2-methylquinoline-4,6-diamine Chemical compound N1=C(C)C=C(N(C)C)C2=CC(NC=3N=C(NC=4C=C5C(N)=CC(C)=NC5=CC=4)N=C(N=3)SC)=CC=C21 QKDPMXVGMJXKLC-UHFFFAOYSA-N 0.000 claims description 2
- GZSUIHUAFPHZSU-UHFFFAOYSA-N 9-ethyl-2,3-dihydro-1h-carbazol-4-one Chemical compound C12=CC=CC=C2N(CC)C2=C1C(=O)CCC2 GZSUIHUAFPHZSU-UHFFFAOYSA-N 0.000 claims description 2
- 108010024976 Asparaginase Proteins 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- AXDLCFOOGCNDST-UHFFFAOYSA-N N-methyl-DL-tyrosine Natural products CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 claims description 2
- 101710183280 Topoisomerase Proteins 0.000 claims description 2
- 150000003838 adenosines Chemical class 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 2
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001097 amifostine Drugs 0.000 claims description 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 2
- 230000001548 androgenic effect Effects 0.000 claims description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 2
- 229940044684 anti-microtubule agent Drugs 0.000 claims description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 2
- 229960000605 dexrazoxane Drugs 0.000 claims description 2
- 229940088598 enzyme Drugs 0.000 claims description 2
- 230000001076 estrogenic effect Effects 0.000 claims description 2
- 150000005699 fluoropyrimidines Chemical class 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 229940022353 herceptin Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 150000003057 platinum Chemical class 0.000 claims description 2
- 150000003230 pyrimidines Chemical class 0.000 claims description 2
- 150000003248 quinolines Chemical group 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims description 2
- 229930002330 retinoic acid Natural products 0.000 claims description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 2
- 229960005314 suramin Drugs 0.000 claims description 2
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- 229960001727 tretinoin Drugs 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 230000010534 mechanism of action Effects 0.000 abstract description 2
- 238000011275 oncology therapy Methods 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 130
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- 239000000203 mixture Substances 0.000 description 50
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 42
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- 239000002244 precipitate Substances 0.000 description 32
- 238000003756 stirring Methods 0.000 description 26
- 238000010992 reflux Methods 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 24
- 238000000034 method Methods 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- 239000012153 distilled water Substances 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- COCFIBRMFPWUDW-UHFFFAOYSA-N CC1=CC(N)=C2C=CC=CC2=N1 Chemical compound CC1=CC(N)=C2C=CC=CC2=N1 COCFIBRMFPWUDW-UHFFFAOYSA-N 0.000 description 17
- 238000002844 melting Methods 0.000 description 15
- 230000008018 melting Effects 0.000 description 15
- 239000002585 base Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 0 *C1=NC(C[Ar])=NC(*[Ar])=N1.[Ar] Chemical compound *C1=NC(C[Ar])=NC(*[Ar])=N1.[Ar] 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000007787 solid Substances 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- YFRCFKDNLUHUPF-UHFFFAOYSA-N 4-n,4-n,2-trimethylquinoline-4,6-diamine Chemical compound C1=C(N)C=C2C(N(C)C)=CC(C)=NC2=C1 YFRCFKDNLUHUPF-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- MCLXKFUCPVGZEN-UHFFFAOYSA-N 4,6-dichloro-1,3,5-triazin-2-amine Chemical compound NC1=NC(Cl)=NC(Cl)=N1 MCLXKFUCPVGZEN-UHFFFAOYSA-N 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- XKDPIURMGBVXAB-UHFFFAOYSA-N 2-methylquinoline-4,6-diamine Chemical compound C1=C(N)C=CC2=NC(C)=CC(N)=C21 XKDPIURMGBVXAB-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000921 elemental analysis Methods 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 4
- 239000003880 polar aprotic solvent Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- XSGBGXGANHOTDI-UHFFFAOYSA-N 1,2-dimethylquinolin-1-ium-4,6-diamine;chloride;hydrochloride Chemical compound Cl.[Cl-].C1=C(N)C=CC2=[N+](C)C(C)=CC(N)=C21 XSGBGXGANHOTDI-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 3
- ZPTFYJKAWRUABO-UHFFFAOYSA-N 4-n,2-dimethylquinoline-4,6-diamine Chemical compound C1=C(N)C=C2C(NC)=CC(C)=NC2=C1 ZPTFYJKAWRUABO-UHFFFAOYSA-N 0.000 description 3
- MAMDZKZXIGHWCS-UHFFFAOYSA-N COC1=C2C=CC=CC2=NC(C)=C1 Chemical compound COC1=C2C=CC=CC2=NC(C)=C1 MAMDZKZXIGHWCS-UHFFFAOYSA-N 0.000 description 3
- QWIFPURWTSVNGN-UHFFFAOYSA-N Cc(cc12)ccc1nc(C)cc2N Chemical compound Cc(cc12)ccc1nc(C)cc2N QWIFPURWTSVNGN-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000005576 amination reaction Methods 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- QEJJTUPQGGEUFD-UHFFFAOYSA-N n-(4-methoxy-2-methylquinolin-6-yl)acetamide Chemical compound C1=C(NC(C)=O)C=C2C(OC)=CC(C)=NC2=C1 QEJJTUPQGGEUFD-UHFFFAOYSA-N 0.000 description 3
- AGJFILRSOJUPOM-UHFFFAOYSA-N n-(9-amino-10-methylacridin-10-ium-2-yl)acetamide;chloride;hydrochloride Chemical compound Cl.[Cl-].C1=CC=CC2=C(N)C3=CC(NC(=O)C)=CC=C3[N+](C)=C21 AGJFILRSOJUPOM-UHFFFAOYSA-N 0.000 description 3
- QRBTWPRLHANALE-UHFFFAOYSA-N n-(9-amino-10-methylacridin-10-ium-2-yl)acetamide;sulfate Chemical compound [O-]S([O-])(=O)=O.C1=CC=CC2=C(N)C3=CC(NC(=O)C)=CC=C3[N+](C)=C21.C1=CC=CC2=C(N)C3=CC(NC(=O)C)=CC=C3[N+](C)=C21 QRBTWPRLHANALE-UHFFFAOYSA-N 0.000 description 3
- PSXXCXSMBDHBDN-UHFFFAOYSA-N n-(9-aminoacridin-2-yl)acetamide Chemical compound C1=CC=CC2=C(N)C3=CC(NC(=O)C)=CC=C3N=C21 PSXXCXSMBDHBDN-UHFFFAOYSA-N 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- WUIDKVCYKAPOKI-UHFFFAOYSA-N 4,6-dichloro-2-methylsulfanyl-1h-triazine Chemical compound CSN1NC(Cl)=CC(Cl)=N1 WUIDKVCYKAPOKI-UHFFFAOYSA-N 0.000 description 2
- AQGPBQYRJAGGQI-UHFFFAOYSA-N 4,6-dichloro-n-methyl-1h-triazin-2-amine Chemical compound CNN1NC(Cl)=CC(Cl)=N1 AQGPBQYRJAGGQI-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- LUHYAOUKGPHLIP-UHFFFAOYSA-N CC1=CC(=N)C2=C(C=CC=C2)N1C.Cl Chemical compound CC1=CC(=N)C2=C(C=CC=C2)N1C.Cl LUHYAOUKGPHLIP-UHFFFAOYSA-N 0.000 description 2
- ZTNANFDSJRRZRJ-UHFFFAOYSA-N CC1=CC(C)=C2C=CC=CC2=N1 Chemical compound CC1=CC(C)=C2C=CC=CC2=N1 ZTNANFDSJRRZRJ-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000001099 anti-trypanosomal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000007978 cacodylate buffer Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LRMDXTVKVHKWEK-UHFFFAOYSA-N 1,2-diaminoanthracene-9,10-dione Chemical class C1=CC=C2C(=O)C3=C(N)C(N)=CC=C3C(=O)C2=C1 LRMDXTVKVHKWEK-UHFFFAOYSA-N 0.000 description 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical class C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
- AYCRQVQFBBYUER-UHFFFAOYSA-N 1-methyl-2h-quinoline-4,6-diamine Chemical compound NC1=CC=C2N(C)CC=C(N)C2=C1 AYCRQVQFBBYUER-UHFFFAOYSA-N 0.000 description 1
- ATJLZNHRDGHBQQ-UHFFFAOYSA-M 1-methylquinolin-1-ium-6-amine;chloride;hydrochloride Chemical compound Cl.[Cl-].NC1=CC=C2[N+](C)=CC=CC2=C1 ATJLZNHRDGHBQQ-UHFFFAOYSA-M 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- OMRXVBREYFZQHU-UHFFFAOYSA-N 2,4-dichloro-1,3,5-triazine Chemical compound ClC1=NC=NC(Cl)=N1 OMRXVBREYFZQHU-UHFFFAOYSA-N 0.000 description 1
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- UJVBZCCNLAAMOV-UHFFFAOYSA-N 2h-1,2-benzothiazine Chemical compound C1=CC=C2C=CNSC2=C1 UJVBZCCNLAAMOV-UHFFFAOYSA-N 0.000 description 1
- CMLFRMDBDNHMRA-UHFFFAOYSA-N 2h-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- JLGXLMTWXPWSJR-UHFFFAOYSA-N 4,6-dichloro-n,n-dimethyl-1h-triazin-2-amine Chemical compound CN(C)N1NC(Cl)=CC(Cl)=N1 JLGXLMTWXPWSJR-UHFFFAOYSA-N 0.000 description 1
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical compound C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- SVHMVYMDQMUMJH-UHFFFAOYSA-N 6-[[4-[(4-amino-2-methylquinolin-6-yl)amino]-6-methylsulfanyl-1,3,5-triazin-2-yl]amino]-2-methyl-1h-quinolin-4-one Chemical compound N1=C(C)C=C(O)C2=CC(NC=3N=C(NC=4C=C5C(N)=CC(C)=NC5=CC=4)N=C(N=3)SC)=CC=C21 SVHMVYMDQMUMJH-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- RCKNDOZXXYZFQO-UHFFFAOYSA-N CC1=CC(N(C)C)=C2C=CC=CC2=N1 Chemical compound CC1=CC(N(C)C)=C2C=CC=CC2=N1 RCKNDOZXXYZFQO-UHFFFAOYSA-N 0.000 description 1
- SMUQFGGVLNAIOZ-UHFFFAOYSA-N CC1=CC=C2C=CC=CC2=N1 Chemical compound CC1=CC=C2C=CC=CC2=N1 SMUQFGGVLNAIOZ-UHFFFAOYSA-N 0.000 description 1
- NRGGMCIBEHEAIL-UHFFFAOYSA-N CCC1=NC=CC=C1 Chemical compound CCC1=NC=CC=C1 NRGGMCIBEHEAIL-UHFFFAOYSA-N 0.000 description 1
- PLAZXGNBGZYJSA-UHFFFAOYSA-N CCN1C2=C(C=CC=C2)C2=C1C=CC=C2 Chemical compound CCN1C2=C(C=CC=C2)C2=C1C=CC=C2 PLAZXGNBGZYJSA-UHFFFAOYSA-N 0.000 description 1
- HFDLDPJYCIEXJP-UHFFFAOYSA-N COC1=CC2=CC=CN=C2C=C1 Chemical compound COC1=CC2=CC=CN=C2C=C1 HFDLDPJYCIEXJP-UHFFFAOYSA-N 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- XRCSYMVDLYGKTE-UHFFFAOYSA-N Cc1cc(C(N)=N)ccc1 Chemical compound Cc1cc(C(N)=N)ccc1 XRCSYMVDLYGKTE-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N N#CC1=CC=CC=C1 Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- FCXMXTMQASDIDU-UHFFFAOYSA-N acridine-2,9-diamine Chemical compound C1=CC=CC2=C(N)C3=CC(N)=CC=C3N=C21 FCXMXTMQASDIDU-UHFFFAOYSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-O hydron;quinoline Chemical compound [NH+]1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-O 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229950008745 losoxantrone Drugs 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- JBTFFRGMIAACAO-UHFFFAOYSA-N n,n'-bis(7-chloroquinolin-4-yl)pentane-1,5-diamine Chemical compound ClC1=CC=C2C(NCCCCCNC=3C4=CC=C(C=C4N=CC=3)Cl)=CC=NC2=C1 JBTFFRGMIAACAO-UHFFFAOYSA-N 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 108091035233 repetitive DNA sequence Proteins 0.000 description 1
- 102000053632 repetitive DNA sequence Human genes 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- IXBPPZBJIFNGJJ-UHFFFAOYSA-N sodium;cyanoiminomethylideneazanide Chemical compound [Na+].N#C[N-]C#N IXBPPZBJIFNGJJ-UHFFFAOYSA-N 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
- C07D251/70—Other substituted melamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Definitions
- the present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
- the present invention relates to the use of novel non-nucleotide chemical compounds which interact with specific structures of deoxyribonucleic acid (DNA).
- DNA deoxyribonucleic acid
- novel compounds consist of a distribution agent linked to two aminoaromatic groups.
- These novel compounds are useful in the treatment of cancers and act in particular as telomerase-inhibiting agents. They are particularly useful for stabilizing DNA in G-quadruplex structure (guanine tetrads).
- the therapeutic application of the inhibition of telomerase via the stabilization of these G-quadruplexes is the termination of cellular mitosis and the death of rapidly dividing cells such as cancer cells and possibly the induction of the senescence of cancer cells.
- the compounds of the present invention have the advantage, from the therapeutic point of view, of blocking telomerase.
- telomerase allows the addition of repetitive DNA sequences of the T T A G G type, termed telomeric sequences, at the end of the telomer, during cell division.
- telomerase renders the cell immortal. Indeed, in the absence of this enzymatic activity, the cell loses, at each division, 100 to 150 bases, which rapidly renders it senescent.
- telomers which were maintained at a stable length during cell division.
- telomerase was highly activated and that it allowed the addition of repetitive motifs of telomeric sequences at the end of the telomer and therefore allowed conservation of the length of the telomer in the cancer cells. It appeared for some time that more than 85% of cancer cells showed positive tests for the presence of telomerase whereas somatic cells do not show this characteristic.
- telomerase is a highly renowned target for treating cancer cells.
- the first obvious approach for blocking telomerase was the use of nucleotide structures (Chen et al., Proc. Natl. Acad. Sci. USA 93(7), 2635-2639).
- nucleotide structures Chon et al., Proc. Natl. Acad. Sci. USA 93(7), 2635-2639.
- non-nucleotide compounds which have been used in the prior art, there may be mentioned the diaminoanthraquinones (Sun et al., J. Med. Chem. 40(14), 2113-6) or the diethyloxadicarbocyanins (Wheelhouse R. T. et al., J. Am. Chem. Soc. 1998(120), 3261-2).
- Patent WO 99/40087 describes the use of compounds which interact with the G-quadruplex structures which are perylene compounds and carbocyanins containing at least seven rings including two heterocycles.
- the nitrogen-containing aromatic ring represents:
- a quinoline optionally substituted with at least one group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen or a short-chain C1-C4 alkyl and/or alkoxy radical and/or
- a quinoline optionally substituted with at least one group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen or a short-chain C1-C4 alkyl and/or alkoxy radical and/or
- a phenyl ring optionally substituted at the meta or para position with a halogen group, C1-C4 alkoxy group, cyano group, carbonylamino group optionally substituted with one or more C1-C4 alkyl groups, guanyl groups, C1-C4 alkylthio groups, amino groups, C1-C4 alkylamino groups, C1-C4 dialkylamino groups for each alkyl group, nitro group, alkyleneamino group or alkenyleneamino group or
- a mono- or bi- or tricyclic heterocyclic ring comprising 0 to 2 heteroatoms per ring provided that at least one heteroatom is present in at least one ring optionally substituted with one or more C1-C4 alkyl groups or with alkylene or alkenylene groups
- R3 and R′3, which are identical or different, represent independently of one another hydrogen or a C1-C4 alkyl radical
- the distribution agent represents:
- a triazine group optionally substituted with an alkyl radical having 1 to 4 carbon atoms, a thio, oxy or amino radical which are themselves optionally substituted with one or more short-chain alkyl chains containing 1 to 4 carbon atoms or a halogen atom or
- a diazine group optionally substituted with the same groups as the triazine or one of its salts.
- nitrogen-containing aromatic ring is understood to mean a heterocycle comprising at least one nitrogen atom or an aromatic group containing no heteroatom in the ring but containing at least one nitrogen atom in a hydrocarbon chain attached to the ring, such as for example a guanidino or guanyl chain.
- A represents
- R1 and R2 which are identical or different, represent hydrogen or a straight or branched alkyl group containing 1 to 4 carbon atoms or
- a halogen atom chosen from fluorine, chlorine, bromine or iodine
- R3 and R′3, which are identical or different, represent independently of one another hydrogen or a C1-C4 alkyl radical
- Ar 1 and Ar 2 which are identical or different, represent
- a quinoline motif optionally substituted with at least one group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen or a short-chain alkyl and/or alkoxy radical containing 1 to 4 carbon atoms or
- Ar 1 and Ar 2 both represent one of the possibilities mentioned above for Ar 1 and Ar 2 or
- Ar 1 represents one of the above possibilities and Ar 2 represents
- a phenyl ring optionally substituted at the meta or para position with a halogen group, C1-C4 alkoxy group, cyano group, carbonylamino group optionally substituted with one or more C1-C4 alkyl groups, guanyl groups, C1-C4 alkylthio groups, amino groups, C1-C4 alkylamino groups, C1-C4 dialkylamino groups for each alkyl group, nitro group, alkyleneamino group or alkenyleneamino group
- a mono- or bi- or tricyclic heterocyclic ring comprising 0 to 2 heteroatoms per ring provided that at least one heteroatom is present in at least one ring optionally substituted with one or more C1-C4 alkyl groups or with alkylene or alkenylene groups
- quinoline motifs may e substituted by any other group not involved in the intended application; thus, acridine or isoquinoline or quinazoline or quinoxaline or phthalazine or benzothiazine or benzoxazine or phenoxazine or phenothiazine groups are included in the definition of the quinoline groups.
- R1 and R2 groups preferably represent the methylthio, amino, alkylamino or dialkylamino radical, in which radicals the alkyl groups possess 1 to 4 carbon atoms.
- the following compounds may be mentioned by way of representative compounds of formula (I):
- Another subject of the present invention relates to the compounds of formula (I) as novel chemical products. It therefore relates to the novel products corresponding to the following formula (I):
- A represents
- a halogen atom chosen from fluorine, chlorine, bromine or iodine
- R 3 and R′ 3 which are identical or different, represent independently of one another a hydrogen atom or a C1-C4 alkyl group
- Ar 1 and Ar 2 which are identical or different, represent
- a quinoline motif optionally substituted with at least one group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen or a short-chain alkyl and/or alkoxy radical containing 1 to 4 carbon atoms and/or
- Ar 1 and Ar 2 both represent one of the possibilities mentioned above for Ar 1 and Ar 2 or
- Ar 1 represents one of the above possibilities and Ar 2 represents
- a phenyl ring optionally substituted at the meta or para position with a halogen group, C1-C4 alkoxy group, cyano group, carbonylamino group optionally substituted with one or more C1-C4 alkyl groups, guanyl groups, C1-C4 alkylthio groups, amino groups, C1-C4 alkylamino groups, C1-C4 dialkylamino groups for each alkyl group, nitro group, alkyleneamino group or alkenyleneamino group
- a mono- or bi- or tricyclic heterocyclic ring comprising 0 to 2 heteroatoms per ring provided that at least one heteroatom is present in at least one ring optionally substituted with one or more C1-C4 alkyl groups or with alkylene or alkenylene groups
- the compounds of formula (I) which are preferred are those for which Ar 1 and Ar 2 represent a group chosen from the following motifs: 4-amino- or 4-methylamino- or 4-dimethylamino-quinolyl or quinolinium in which the quinolinium ring is optionally substituted with a methyl group.
- the compounds of general formula (I) which are preferred are those for which A represents an amino or dimethylamino or, more preferably, methylthio group.
- Ar 1 represents:
- a quinoline possessing a nitrogen atom in quaternary form or a benzamidine except in the case where A represents diethylamine, hydrogen or an amine group or
- a phenyl ring optionally substituted at the meta or para position with a halogen, methoxy, cyano, carbonylamino, guanyl, methylthio, amino, methylamino, dimethylamino, morpholine, alkyleneamino or alkenyleneamino group
- Another subject of the present invention relates to the use of the compounds of formula (I) as pharmaceutical product for human use.
- compounds of general formula (I) in which Ar 1 and Ar 2 are identical and defined as above and R represents a halogen atom such as chlorine or fluorine, an amino, alkylamino or dialkylamino function in which the straight or branched alkyl portions contain from 1 to 4 carbon atoms, an alkyloxy or alkylthio function in which the straight or branched alkyl portions contain from 1 to 4 carbon atoms, may be obtained by amination of a dihalotriazine, most generally a dichloros-triazine, of general formula (B) in which A is as defined above, with an aromatic or heteroaromatic amine of general formula (C) in which Ar is as defined above, the procedure being carried out according to scheme 1:
- the procedure is generally carried out by condensing one mole of dihalo-s-triazine, or trihalos-triazine, with 2 moles of aromatic or heteroaromatic amine.
- the reaction takes place in an inert medium under the reaction conditions.
- the inert solvents There may be mentioned, among the inert solvents, acetone which is optionally aqueous or an alcohol which is optionally aqueous such as ethanol, or a halogenated solvent such as dichloromethane, or an ether such as diethyl ether or dioxane, or a polar aprotic solvent such as DMF, DMSO or NMP.
- the procedure is preferably carried out at a temperature of between 20° C.
- dihalo- or trihalo-s-triazines of general formula (B) are either commercially available or are known, and may be obtained under the conditions described in the literature.
- aromatic or heteroaromatic amines of general formula (C) are either known or may be easily prepared by the known methods of synthesizing aromatic or heteroaromatic amines.
- the triazine of general formula (A) may be obtained by sequential displacement of the halogen atoms, most generally of the chlorine atoms, from the products of general formula (B) by the amines Ar 1 and then Ar 2 of general formula (C) according to scheme 2:
- the procedure is carried out with 1 mole of dihalo-s-triazine, or trihalo-s-triazine, and 1 mole of amine Ar 1 .
- the procedure is preferably carried out in an inert solvent such as acetone which is optionally aqueous or an alcohol which is optionally aqueous, such as ethanol, or a halogenated solvent such as dichloromethane, or an ether such as diethyl ether or dioxane, or a polar aprotic solvent such as DMF, DMSO or NMP.
- an inert solvent such as acetone which is optionally aqueous or an alcohol which is optionally aqueous, such as ethanol, or a halogenated solvent such as dichloromethane, or an ether such as diethyl ether or dioxane, or a polar aprotic solvent such as DMF, DMSO or NMP.
- the procedure is carried out at a temperature of between 20
- the products of general formula (A) in which Ar are as defined above and R represents a group NR1R2 or OR1 or SR1 may also be prepared by nucleophilic displacement of a halogen atom, generally a chlorine atom, from a product of general formula (A) in which R represents a halogen atom according to scheme 3:
- the procedure is generally carried out by condensing 1 mole of product of general formula (A) in which R represents a halogen atom, preferably a chlorine atom, with 1 mole of amine R1R2NH or alcoholate R1O ⁇ or thioalcoholate R1S.
- the reaction takes place in an inert medium under the reaction conditions.
- the inert solvent acetone which is optionally aqueous or an alcohol which is optionally aqueous such as ethanol, or a halogenated solvent such as dichloromethane, or an ether such as diethyl ether or dioxane, or a polar aprotic solvent such as DMF, DMSO or NMP.
- the procedure is preferably carried out at a temperature of between 20° C. and the reflux temperature, in the presence in particular of an organic base such as triethylamine, or an inorganic base such as sodium hydroxide or sodium or potassium carbonate. It is also possible not to use a base during the amination reaction, and to isolate a hydrochloride of the product of general formula (A), the base of which can then be released.
- an organic base such as triethylamine
- an inorganic base such as sodium hydroxide or sodium or potassium carbonate. It is also possible not to use a base during the amination reaction, and to isolate a hydrochloride of the product of general formula (A), the base of which can then be released.
- the procedure is preferably carried out with an alkali metal or alkaline-earth metal alcoholate or thioalcoholate, such as a sodium or potassium or lithium or ammonium or caesium or barium salt, in a polar aprotic solvent such as DMF or DMSO or NMP, at a temperature of between 50° C. and the reflux temperature.
- an alkali metal or alkaline-earth metal alcoholate or thioalcoholate such as a sodium or potassium or lithium or ammonium or caesium or barium salt
- a polar aprotic solvent such as DMF or DMSO or NMP
- the compounds for which R represents a hydrogen atom or a straight or branched alkyl group containing from 1 to 4 carbon atoms may also be prepared by condensation of a bisguanide of general formula (E), in which Ar 1 and Ar 2 are identical or different, with an acid derivative, preferably an acid chloride or a methyl ester of general formula (F) according to scheme 4:
- the condensation between the bisguanide of general formula (E) and the acid derivative of general formula (F) is generally carried out in an alcohol such as methanol or ethanol.
- the procedure is preferably carried out at a temperature of between 0° C. and the reflux temperature.
- the symmetric or asymmetric bisguanides of general formula (E) may be obtained by carrying out the procedure under the conditions described in the literature and in particular according to Patent J.P. 94-4993.
- cyanoguanidines of general formula (G) may be prepared under the conditions described in the literature.
- the s-triazines of general formula may be obtained in the form of libraries, by applying the methods described in schemes 1, 2, 3, 4 or 5 in parallel and/or combinatorial chemistry in liquid phase or in solid phase, it being understood that when the work is carried out in solid phase, any of the reagents is attached beforehand onto a solid support, chosen according to the chemical reaction involved, and that said chemical reaction is followed by an operation of cleaving the product of the reaction from the solid support.
- the present invention also relates to therapeutic compositions containing a compound according to the invention, in combination with a pharmaceutically acceptable carrier according to the mode of administration chosen.
- the pharmaceutical composition may be provided in solid, liquid or liposome form.
- the solid compositions there may be mentioned powders, gelatin capsules and tablets.
- the oral forms it is also possible to include the solid forms which are protected from the acidic medium of the stomach.
- the carriers used for the solid forms consist in particular of inorganic carriers such as phosphates, carbonates or organic carriers such as lactose, celluloses, starch or polymers.
- the liquid forms consist of solutions, suspensions or dispersions. They contain, as dispersive carrier, either water or an organic solvent (ethanol, NMP and the like) or mixtures of surfactants and solvents or of complexing agents and solvents.
- the administered dose of the compounds of the invention will be adjusted by the practitioner according to the route of administration, the patient and the condition of the latter.
- the compounds of the present invention may be administered alone or mixed with other anticancer agents. Among the possible combinations, there may be mentioned
- alkylating agents and in particular cyclophosphamide, melphalan, ifosfamide, chlorambucil, busulfan, thiotepa, prednimustine, carmustine, lomustine, semustine, streptozotocin, decarbazine, temozolomide, procarbazine and hexamethylmelamine
- platinum derivatives such as in particular cisplatin, carboplatin or oxaliplatin
- antibiotic agents such as in particular bleomycin, mitomycin, dactinomycin,
- antimicrotubule agents such as in particular vinblastine, vincristine, vindesine, vinorelbine, taxoids (paclitaxel and docetaxel)
- anthracyclines such as in particular doxorubicin, daunorubicin, idarubicin, epirubicin, mitoxantrone, losoxantrone
- group I and II topoisomerases such as etoposide, teniposide, amsacrine, irinotecan, topotecan and tomudex,
- fluoropyrimidines such as 5-fluorouracil, UFT, floxuridine,
- cytidine analogues such as 5-azacytidine, cytarabine, gemcitabine, 6-mercaptomurine, 6-thioguanine
- adenosine analogues such as pentostatin, cytarabine or fludarabine phosphate
- a radiation treatment with the compounds of the present invention.
- This treatment may be administered simultaneously, separately or sequentially.
- the treatment will be adapted to the patient to be treated by the practitioner.
- the G-quadruplex stabilizing activity may be determined by a method using the formation of a complex with fluorescein of which the experimental protocol is described below.
- the oligonucleotide FAM+DABCYL carries the catalogue reference OL-0371-0802. It has the sequence: GGGTTAGGGTTAGGGTTAGGG corresponding to 3.5 repeats of the human telomeric motif (strand rich in G).
- the fluorescein is attached to the 5′ end, the DABCYL to the 3′ end, by the chemical arms described by Eurogentec.
- the concentration of the samples is checked by spectrophotometry, recording the absorbance spectrum between 220 and 700 nm and using the molar extinction coefficient provided by the supplier.
- Each experiment allows the measurement of only one sample.
- the latter is first incubated at an initial temperature of 20° C., heated to 80° C. over 38 minutes, left for 5 minutes at 80° C. and then cooled to 20° C. over 62 minutes.
- the fluorescence is measured simultaneously at two emission wavelengths (515 nm and 588 nm) using 470 nm as excitation wavelength.
- a measurement is carried out every 30 seconds.
- the temperature of the water bath is recorded in parallel, and the fluorescence profile as a function of the temperature is reconstituted from these values.
- the fluorescence profiles are then normalized between 20° C.
- Tm the temperature for which the intensity of emission at 515 nm is the mean of those at high and low temperature.
- the Tm of the reference sample without addition of product is 44° C. in a lithium chloride buffer. This temperature is increased to more than 55° C. in a sodium chloride buffer.
- the addition of a G-quadruplex-stabilizing compound induces an increase in the Tm. This increase is judged to be significant if it is greater than 30.
- the antitelomerase biological activity is determined by the following experimental protocol:
- the leukaemia line HL60 is obtained from ATCC (American Type Culture Collection, Rockville, USA). The cells are cultured in suspension in RPMI 1640 medium containing L-glutamine at 2 mM, penicillin 200 U/ml, streptomycin 200 ⁇ g/ml, gentamycin 50 ⁇ g/ml and supplemented with 10% heat-inactivated foetal calf serum.
- the inhibition of the telomerase activity is determined by a protocol for extension of the oligonucleotide TS ( 5′ AATCGTTCGAGCAGAGTT 3′ ), in the presence of a cellular extract enriched in telomerase activity and compounds which are added at various concentrations (10, 1, 0.1 and 0.01 ⁇ g/ml).
- the extension reaction is followed by a PCR amplification of the extension products with the aid of the oligonucleotides TS and CXext ( 5′ GTGCCCTTACCCTTACCCTTACCCTAA 3′ ).
- the reaction medium is prepared based on the following composition: Tris HCl pH 8.3 20 mN MgCl2 1.5 mM Tween 20 0.005% (P/V) EGTA 1 mM dATP 50 ⁇ M dGTP 50 ⁇ M dCTP 50 ⁇ M dTTP 50 ⁇ M Oligonucleotide TS 2 ⁇ g/ml Oligonucleotide CXext 2 ⁇ g/ml Bovine serum albumin 0.1 mg/ml Taq DNA polymerase 1 U/ml alpha 32P dCTP (3000 Ci/mmol) 0.5 ⁇ l Telomerase extract 200 ng in a volume of 10 ⁇ l Test product or solvent in a volume of 5 ⁇ l Double-distilled water QS. . . 50 ⁇ l
- the oligonucleotides are obtained from Eurogentec (Belgium) and are stored at ⁇ 20° C. at a stock concentration of 1 mg/ml in distilled water.
- reaction samples are assembled in 0.2 ml PCR tubes and one drop of paraffin oil is deposited on each of the reactions of the experiment before closing the tubes.
- reaction samples are then incubated in a Cetus 4800-type PCR apparatus under the following temperature conditions:
- the acrylamide gels are then dried on a sheet of whatmann 3MM paper at 80° C. for 1 hour.
- the concentration of compound inducing a 50% inhibition of the telomerase reaction (IC50) is determined with the aid of a semilogarithmic graphical representation of the inhibition values obtained as a unction of each of the compound concentrations tested.
- a compound is considered to be active as an antitelomerase agent when the quantity inhibiting 50% of the telomerase reaction is in particular less than 5 ⁇ M.
- the human cell lines KB and A549 are obtained from ATCC (American Type Culture Collection, Rockville, USA).
- the A549 cells are cultured in a layer in a culture flask in RPMI 1640 medium containing L-glutamine at 2 mM, penicillin 200 U/ml, streptomycin 200 ⁇ g/ml and supplemented with 10% heat-inactivated foetal calf serum.
- the KB cells are cultured in a layer in a culture flask in Dulbelco's medium containing L-glutamine at 2 mM, penicillin 200 U/ml, streptomycin 200 ⁇ g/ml and supplemented with 10% heat-inactivated foetal calf serum.
- the cells at the exponential growth phase are trypsinized, washed in 1 ⁇ PBS and are inoculated in 96-well microplates (Costar) in an amount of 4 ⁇ 10 4 cells/ml for A549 and of 1.5 ⁇ 10 4 cells/ml (0.2 ml/well) and then incubated for 96 hours in the presence of variable concentrations of product to be studied (10, 1, 0.1 and 0.01 ⁇ g/ml, each point in quadruplicate). 16 hours before the end of the incubation, 0.02% final of neutral red is added to each well. At the end of the incubation, the cells are washed with 1 ⁇ PBS and lysed with 1% sodium lauryl sulphate. The cellular incorporation of the dye, which reflects cellular growth, is evaluated by spectrophotometry at a wavelength of 540 nm for each sample with the aid of a Dynatech MR5000 reading apparatus.
- the concentration of compound inducing a 50% inhibition of growth (IC50) is determined with the aid of a semilogarithmic graphical representation of the inhibition values obtained as a function of each of the compound concentrations tested.
- a compound is considered to be active as cytotoxic agent if the concentration inhibiting the growth of the tumour cells tested by 50% is in particular less than 10 ⁇ M.
- a yellow solution is obtained into which 900 cm 3 of ethanol are poured, causing an abundant precipitate. After dissolution by heating to 50° C., 14.8 g (0.09 mol) of 2-amino-4,6-dichlorotriazine are added, and the mixture is heated under reflux for 1 hour; a yellow precipitate appears rapidly. The mixture is cooled overnight on an ice bath and then the precipitate obtained is filtered, washed with twice 50 cm 3 of ethanol, dried and 36.6 g (79%) of 2-aminobis-4,6-[(1′-methyl-6′-quinolinio)amino]triazine dichloride monohydrochloride are obtained.
- the mixture is then heated at 100° C. for 11 hours and then it is left overnight on an ice bath.
- the crystallized product is filtered, giving 25 g of hydrochloride, the mother liquors are concentrated, left overnight on an ice bath and then filtered to give again 150 g of hydrochloride.
- the 175 g of hydrochloride are taken up in 300 cm 3 of distilled water and dissolved by heating to 50° C., treated with 1 g of charcoal and filtered on Supercel.
- the filtrate is heated to 90° C. and alkalinized by addition of 54 cm 3 of concentrated sodium hydroxide.
- the precipitate obtained by cooling overnight on an ice bath is washed with four times 100 cm 3 of distilled water, dried and 33 g (70%) of 4-methylamino-6-aminoquinaldine are obtained.
- Step B Preparation of 2-acetamido-9-amino-10-methylacridinium sulphate
- Step C Preparation of 2-acetamido-9-amino-10-methylacridinium Chloride Hydrochloride
- This product may be obtained according to J. Chem. Soc., 1960, 4525, in the form of a hygroscopic cream-coloured powder.
- N,N′-(4-amino-6-quinaldinyl)urea dihydrochloride (the corresponding base, also called SURFENE, may be prepared according to Ang. Chem 1939, 891)
Abstract
The present invention relates to cancer therapy and to novel anticancer agent having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
Description
- The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
- The present invention relates to the use of novel non-nucleotide chemical compounds which interact with specific structures of deoxyribonucleic acid (DNA). These novel compounds consist of a distribution agent linked to two aminoaromatic groups. These novel compounds are useful in the treatment of cancers and act in particular as telomerase-inhibiting agents. They are particularly useful for stabilizing DNA in G-quadruplex structure (guanine tetrads). The therapeutic application of the inhibition of telomerase via the stabilization of these G-quadruplexes is the termination of cellular mitosis and the death of rapidly dividing cells such as cancer cells and possibly the induction of the senescence of cancer cells.
- The compounds of the present invention have the advantage, from the therapeutic point of view, of blocking telomerase. From a biological point of view, telomerase allows the addition of repetitive DNA sequences of the T T A G G G type, termed telomeric sequences, at the end of the telomer, during cell division. Through this action, telomerase renders the cell immortal. Indeed, in the absence of this enzymatic activity, the cell loses, at each division, 100 to 150 bases, which rapidly renders it senescent. During the appearance of rapidly dividing cancer cells, it appeared that these cells possessed telomers which were maintained at a stable length during cell division. In these cancer cells, it appeared that telomerase was highly activated and that it allowed the addition of repetitive motifs of telomeric sequences at the end of the telomer and therefore allowed conservation of the length of the telomer in the cancer cells. It appeared for some time that more than 85% of cancer cells showed positive tests for the presence of telomerase whereas somatic cells do not show this characteristic.
- Thus, telomerase is a highly coveted target for treating cancer cells. The first obvious approach for blocking telomerase was the use of nucleotide structures (Chen et al., Proc. Natl. Acad. Sci. USA 93(7), 2635-2639). Among the non-nucleotide compounds which have been used in the prior art, there may be mentioned the diaminoanthraquinones (Sun et al., J. Med. Chem. 40(14), 2113-6) or the diethyloxadicarbocyanins (Wheelhouse R. T. et al., J. Am. Chem. Soc. 1998(120), 3261-2).
- Patent WO 99/40087 describes the use of compounds which interact with the G-quadruplex structures which are perylene compounds and carbocyanins containing at least seven rings including two heterocycles.
- It appeared, quite surprisingly, that simple structures made it possible to obtain a result which is at least equivalent with structures which are a lot less complicated from a chemical point of view. The compounds of the present invention which meet the intended objective, that is to say which bind the G-quadruplex structure and thereby exhibit a telomerase-inhibiting activity, correspond to the following general formula:
- nitrogen-containing aromatic ring-NR3-distribution agent-NR′3-aromatic ring
- in which
- the nitrogen-containing aromatic ring represents:
- a quinoline optionally substituted with at least one group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen or a short-chain C1-C4 alkyl and/or alkoxy radical and/or
- a quinoline possessing a nitrogen atom in quaternary form or
- a benzamidine or
- a pyridine
- the aromatic ring represents
- a quinoline optionally substituted with at least one group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen or a short-chain C1-C4 alkyl and/or alkoxy radical and/or
- a quinoline possessing a nitrogen atom in quaternary form or
- a benzamidine or
- a pyridine or
- a phenyl ring optionally substituted at the meta or para position with a halogen group, C1-C4 alkoxy group, cyano group, carbonylamino group optionally substituted with one or more C1-C4 alkyl groups, guanyl groups, C1-C4 alkylthio groups, amino groups, C1-C4 alkylamino groups, C1-C4 dialkylamino groups for each alkyl group, nitro group, alkyleneamino group or alkenyleneamino group or
- a mono- or bi- or tricyclic heterocyclic ring comprising 0 to 2 heteroatoms per ring provided that at least one heteroatom is present in at least one ring optionally substituted with one or more C1-C4 alkyl groups or with alkylene or alkenylene groups
- R3 and R′3, which are identical or different, represent independently of one another hydrogen or a C1-C4 alkyl radical
- the distribution agent represents:
- a triazine group optionally substituted with an alkyl radical having 1 to 4 carbon atoms, a thio, oxy or amino radical which are themselves optionally substituted with one or more short-chain alkyl chains containing 1 to 4 carbon atoms or a halogen atom or
- a carbonyl group or
- a group C(=NH)—NH—C(═NH) or
- an alkyldiyl group containing 3 to 7 carbon atoms or
- a diazine group optionally substituted with the same groups as the triazine or one of its salts.
- For the purposes of the above formula, nitrogen-containing aromatic ring is understood to mean a heterocycle comprising at least one nitrogen atom or an aromatic group containing no heteroatom in the ring but containing at least one nitrogen atom in a hydrocarbon chain attached to the ring, such as for example a guanidino or guanyl chain.
-
- in which:
- A represents
- an amino group of formula NRlR2 in which R1 and R2, which are identical or different, represent hydrogen or a straight or branched alkyl group containing 1 to 4 carbon atoms or
- a group OR1 or SR1 in which R1 has the same meaning as above or
- an alkyl group containing1 to 4 carbon atoms or a trifluoromethyl group or
- a hydrogen atom or
- a halogen atom chosen from fluorine, chlorine, bromine or iodine
- R3 and R′3, which are identical or different, represent independently of one another hydrogen or a C1-C4 alkyl radical
- Ar1 and Ar2, which are identical or different, represent
- 1. when Ar1 and Ar2 are identical:
- a quinoline motif optionally substituted with at least one group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen or a short-chain alkyl and/or alkoxy radical containing 1 to 4 carbon atoms or
- a quinoline possessing a nitrogen atom in quaternary form or
- a benzamidine or
- a pyridine attached at the 4-position or fused with an aryl or heteroaryl group optionally substituted with a C1-C4 alkyl group
- 2. when Ar1 and Ar2 are different
- Ar1 and Ar2 both represent one of the possibilities mentioned above for Ar1 and Ar2 or
- Ar1 represents one of the above possibilities and Ar2 represents
- a phenyl ring optionally substituted at the meta or para position with a halogen group, C1-C4 alkoxy group, cyano group, carbonylamino group optionally substituted with one or more C1-C4 alkyl groups, guanyl groups, C1-C4 alkylthio groups, amino groups, C1-C4 alkylamino groups, C1-C4 dialkylamino groups for each alkyl group, nitro group, alkyleneamino group or alkenyleneamino group
- a mono- or bi- or tricyclic heterocyclic ring comprising 0 to 2 heteroatoms per ring provided that at least one heteroatom is present in at least one ring optionally substituted with one or more C1-C4 alkyl groups or with alkylene or alkenylene groups
- or one of its salts.
- It is evident that the quinoline motifs may e substituted by any other group not involved in the intended application; thus, acridine or isoquinoline or quinazoline or quinoxaline or phthalazine or benzothiazine or benzoxazine or phenoxazine or phenothiazine groups are included in the definition of the quinoline groups.
- Among the above compounds of formula (I), there are preferred those comprising two heterocycles chosen from the 4-aminoquinolyl, 4-aminoquinolinium or quinolinium groups in which the quinolinium ring is optionally substituted with a methyl group.
- As regards the R1 and R2 groups, they preferably represent the methylthio, amino, alkylamino or dialkylamino radical, in which radicals the alkyl groups possess 1 to 4 carbon atoms. The following compounds may be mentioned by way of representative compounds of formula (I):
- 2-amino-bis-4,6-[(1′-methyl-4′-amino-6′-quinaldinio)amino]triazine dichloride
- 2-amino-bis-4,6-[(1′-ethyl-4′-amino-6′-quinaldinio)amino]triazine dichloride
- 2-dimethylamino-bis-4,6-[(1′-methyl-4′-amino-6′-quinaldinio)amino]triazine dichloride
- 2-methylamino-bis-4,6-[(4′-amino-6′-quinaldinyl)amino]triazine trihydrochloride
- 2-amino-bis-4,6-[(1′-methyl-6′-quinolinio)amino]triazine dichloride
- 2-methylamino-bis-4,6-[(4′-methylamino-6′-quinaldinyl)amino]triazine dichloride trihydrochloride
- 2-amino-bis-4,6-[(9′-amino-10′-methyl-2′-acridinio)amino]triazine dichloride hydrochloride
- 2-amino-bis-4,6-[(4′-amino-6′-quinaldinyl)amino]triazine trihydrochloride
- 2-amino-bis-4,6-(p-amidinoanilino)triazine trihydrochloride
- 2-methylthio-bis-4,6-[(1′-methyl-4′-amino-6′-quinaldinio)amino]triazine dichloride
- 2-chloro-bis-4,6-[(4′-dimethylamino-6′-quinaldinyl)amino]triazine dihydrochloride dihydrate
- 2-methylthio-bis-4,6-[(4′-dimethylamino-6′-quinaldinyl)amino]triazine hydrate
- N,N′-(4-amino-6-quinaldinyl)urea dihydrochloride
- N1,N5-bis(7-chloro-1-methyl-4-quinolinio)pentane-1,5-diamine diiodide
- bis-2,4-[(4′-amino-6′-quinaldinyl)amino]pyrimidine trihydrochloride pentahydrate
- 1,5-(4′-amino-6′-quinaldinyl)biguanide trihydrochioride dihydrate
- 6-[4-(4-amino-2-methylquinolin-6-ylamino)6-methylsulphanyl-[1,3,5]triazin-2-ylamino]-2-methyl quinolin-4-ol
- N6-[4-(4-dimethylamino-2-methylquinolin6-ylamino)-6-methylsulphanyl-[1,3,5]triazin-2-yl]2-methylquinoline-4,6-diamine
- N6-[4-(4-amino-2-methylquinolin-6-ylamino)6-methylsulphanyl-[1,3,5]triazin-2-yl]-2-methyl quinoline-4,6-diamine
- N6-[4-(4-methoxy-2-methylquinolin6-ylamino)-6-methylsulphanyl-[1,3,5]triazin-2-yl]4-methoxy-2-methylquinolin-6-amine
-
- in which:
- A represents
- an amino group of formula NRlR2 in which R1 and R2, which are identical or different, represent a straight or branched alkyl group containing 1 to 4 carbon atoms or
- a group OR1 or SR1 in which R1 represents hydrogen or has the same meaning as above or
- an alkyl group containing 1 to 4 carbon atoms or a trifluoromethyl group or
- a hydrogen atom or
- a halogen atom chosen from fluorine, chlorine, bromine or iodine
- R3 and R′3, which are identical or different, represent independently of one another a hydrogen atom or a C1-C4 alkyl group
- Ar1 and Ar2, which are identical or different, represent
- 1. when Ar1 and Ar2 are identical:
- a quinoline motif optionally substituted with at least one group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen or a short-chain alkyl and/or alkoxy radical containing 1 to 4 carbon atoms and/or
- a quinoline possessing a nitrogen atom in quaternary form or
- a benzamidine except in the case where A represents diethylamine, hydrogen or an amine group
- a pyridine attached at the 4-position or fused with an aryl or heteroaryl group optionally substituted with a C1-C4 alkyl group
- 2. when Ar1 and Ar2 are different
- Ar1 and Ar2 both represent one of the possibilities mentioned above for Ar1 and Ar2 or
- Ar1 represents one of the above possibilities and Ar2 represents
- a phenyl ring optionally substituted at the meta or para position with a halogen group, C1-C4 alkoxy group, cyano group, carbonylamino group optionally substituted with one or more C1-C4 alkyl groups, guanyl groups, C1-C4 alkylthio groups, amino groups, C1-C4 alkylamino groups, C1-C4 dialkylamino groups for each alkyl group, nitro group, alkyleneamino group or alkenyleneamino group
- a mono- or bi- or tricyclic heterocyclic ring comprising 0 to 2 heteroatoms per ring provided that at least one heteroatom is present in at least one ring optionally substituted with one or more C1-C4 alkyl groups or with alkylene or alkenylene groups
- or one of its salts excluding 2-amino-bis-4,6-[(4′-amino-6′-quinaldinyl)amino]triazine dihydrochloride and 2-amino-bis-4,6-(p-amidinoanilino)triazine dihydrochloride.
- Indeed, the first of these two compounds is described in a publication which appeared under the reference Indian Journal of Animal Sciences 43(4), pages 226-29, as antitrypanosome agent for animals and in no case as antitelomerase agent and the second compound is also described as antitrypanosome agent in J. Chem. Soc., 1960, 4525.
- The compounds of formula (I) which are preferred are those for which Ar1 and Ar2 represent a group chosen from the following motifs: 4-amino- or 4-methylamino- or 4-dimethylamino-quinolyl or quinolinium in which the quinolinium ring is optionally substituted with a methyl group.
- The compounds of general formula (I) which are preferred are those for which A represents an amino or dimethylamino or, more preferably, methylthio group.
- There are most particularly preferred the compounds of formula (I) for which when Ar1 and Ar2 are different:
- 1. Ar1 represents:
- a quinoline motif substituted with at least one group N(Ra) (Rb) in which Ra and Rb, which are identical or different, represent hydrogen or a short-chain alkyl or alkoxy radical containing 1 to 4 carbon atoms and/or
- a quinoline possessing a nitrogen atom in quaternary form or a benzamidine except in the case where A represents diethylamine, hydrogen or an amine group or
- a pyridine attached at the 4-position or fused with an aryl or heteroaryl group
- 2. Ar2 represents
- a ring as defined above but different or
- a phenyl ring optionally substituted at the meta or para position with a halogen, methoxy, cyano, carbonylamino, guanyl, methylthio, amino, methylamino, dimethylamino, morpholine, alkyleneamino or alkenyleneamino group
- a quinoline, benzimidazole, indole, benzothiophene, benzofuran, benzothiazol, benzoxazol, carbazol, quinazoline or quinoxaline ring optionally substituted with one or more C1-C4 alkyl groups or with alkylene or alkenylene groups
- or one of its salts excluding 2-amino-bis-4,6-[(4′-amino-6′-quinaldinyl)amino]triazine dihydrochloride and 2-amino-bis-4,6-(p-amidinoanilino)-triazine.
- Another subject of the present invention relates to the use of the compounds of formula (I) as pharmaceutical product for human use.
-
- are described below.
- General Method 1
-
- In the case where A represents a halogen atom, it is useful to react the corresponding 2,4,6-trihalo-s-triazine of general formula (B) with the aromatic or heteroaromatic amine ArNH2 of general formula (C).
- The procedure is generally carried out by condensing one mole of dihalo-s-triazine, or trihalos-triazine, with 2 moles of aromatic or heteroaromatic amine. The reaction takes place in an inert medium under the reaction conditions. There may be mentioned, among the inert solvents, acetone which is optionally aqueous or an alcohol which is optionally aqueous such as ethanol, or a halogenated solvent such as dichloromethane, or an ether such as diethyl ether or dioxane, or a polar aprotic solvent such as DMF, DMSO or NMP. The procedure is preferably carried out at a temperature of between 20° C. and the reflux temperature, in the presence in particular of an organic base such as triethylamine, or an inorganic base such as sodium hydroxide or sodium or potassium carbonate. It is also possible not to use a base during the amination reaction, and to isolate a hydrochloride of the product of general formula (A), whose base can then be released.
- The dihalo- or trihalo-s-triazines of general formula (B) are either commercially available or are known, and may be obtained under the conditions described in the literature.
- The aromatic or heteroaromatic amines of general formula (C) are either known or may be easily prepared by the known methods of synthesizing aromatic or heteroaromatic amines.
-
- Generally, the procedure is carried out with 1 mole of dihalo-s-triazine, or trihalo-s-triazine, and 1 mole of amine Ar1. The procedure is preferably carried out in an inert solvent such as acetone which is optionally aqueous or an alcohol which is optionally aqueous, such as ethanol, or a halogenated solvent such as dichloromethane, or an ether such as diethyl ether or dioxane, or a polar aprotic solvent such as DMF, DMSO or NMP. According to a better way of carrying out the invention, the procedure is carried out at a temperature of between 20° C. and 50° C. Next, 1 mole of amine Ar2 is added to the product of general formula (D), which may be optionally isolated. The procedure is carried out in particular at a temperature of between 50° C. and the reflux temperature.
- Advantageously, it is possible to carry out the procedure under the conditions described in J Fluor. Chem., 1988, 39(1), 117-123.
- General Method 2
- According to a second method, the products of general formula (A) in which Ar are as defined above and R represents a group NR1R2 or OR1 or SR1 may also be prepared by nucleophilic displacement of a halogen atom, generally a chlorine atom, from a product of general formula (A) in which R represents a halogen atom according to scheme 3:
- The procedure is generally carried out by condensing 1 mole of product of general formula (A) in which R represents a halogen atom, preferably a chlorine atom, with 1 mole of amine R1R2NH or alcoholate R1O− or thioalcoholate R1S. The reaction takes place in an inert medium under the reaction conditions. There may be mentioned among the inert solvents acetone which is optionally aqueous or an alcohol which is optionally aqueous such as ethanol, or a halogenated solvent such as dichloromethane, or an ether such as diethyl ether or dioxane, or a polar aprotic solvent such as DMF, DMSO or NMP. When the entering group represents a group R1R2NH, the procedure is preferably carried out at a temperature of between 20° C. and the reflux temperature, in the presence in particular of an organic base such as triethylamine, or an inorganic base such as sodium hydroxide or sodium or potassium carbonate. It is also possible not to use a base during the amination reaction, and to isolate a hydrochloride of the product of general formula (A), the base of which can then be released. When the entering group represents a group R1O− or R1S−, the procedure is preferably carried out with an alkali metal or alkaline-earth metal alcoholate or thioalcoholate, such as a sodium or potassium or lithium or ammonium or caesium or barium salt, in a polar aprotic solvent such as DMF or DMSO or NMP, at a temperature of between 50° C. and the reflux temperature.
- General Method 3
-
- The condensation between the bisguanide of general formula (E) and the acid derivative of general formula (F) is generally carried out in an alcohol such as methanol or ethanol. The procedure is preferably carried out at a temperature of between 0° C. and the reflux temperature.
- The symmetric or asymmetric bisguanides of general formula (E) may be obtained by carrying out the procedure under the conditions described in the literature and in particular according to Patent J.P. 94-4993.
- General Method 4
-
- The condensation of the cyanoguanidine of general formula (G) with the nitrile of general formula (H) is in particular performed by carrying out the procedure at the reflux temperature of a polar solvent with a high boiling point such as 2-methoxyethanol or 1,2-dimethoxyethane.
- The cyanoguanidines of general formula (G) may be prepared under the conditions described in the literature.
- It is understood that the s-triazines of general formula may be obtained in the form of libraries, by applying the methods described in schemes 1, 2, 3, 4 or 5 in parallel and/or combinatorial chemistry in liquid phase or in solid phase, it being understood that when the work is carried out in solid phase, any of the reagents is attached beforehand onto a solid support, chosen according to the chemical reaction involved, and that said chemical reaction is followed by an operation of cleaving the product of the reaction from the solid support.
- The present invention also relates to therapeutic compositions containing a compound according to the invention, in combination with a pharmaceutically acceptable carrier according to the mode of administration chosen. The pharmaceutical composition may be provided in solid, liquid or liposome form.
- Among the solid compositions, there may be mentioned powders, gelatin capsules and tablets. Among the oral forms, it is also possible to include the solid forms which are protected from the acidic medium of the stomach. The carriers used for the solid forms consist in particular of inorganic carriers such as phosphates, carbonates or organic carriers such as lactose, celluloses, starch or polymers. The liquid forms consist of solutions, suspensions or dispersions. They contain, as dispersive carrier, either water or an organic solvent (ethanol, NMP and the like) or mixtures of surfactants and solvents or of complexing agents and solvents.
- The administered dose of the compounds of the invention will be adjusted by the practitioner according to the route of administration, the patient and the condition of the latter.
- The compounds of the present invention may be administered alone or mixed with other anticancer agents. Among the possible combinations, there may be mentioned
- alkylating agents and in particular cyclophosphamide, melphalan, ifosfamide, chlorambucil, busulfan, thiotepa, prednimustine, carmustine, lomustine, semustine, streptozotocin, decarbazine, temozolomide, procarbazine and hexamethylmelamine
- platinum derivatives such as in particular cisplatin, carboplatin or oxaliplatin
- antibiotic agents such as in particular bleomycin, mitomycin, dactinomycin,
- antimicrotubule agents such as in particular vinblastine, vincristine, vindesine, vinorelbine, taxoids (paclitaxel and docetaxel)
- anthracyclines such as in particular doxorubicin, daunorubicin, idarubicin, epirubicin, mitoxantrone, losoxantrone
- group I and II topoisomerases such as etoposide, teniposide, amsacrine, irinotecan, topotecan and tomudex,
- fluoropyrimidines such as 5-fluorouracil, UFT, floxuridine,
- cytidine analogues such as 5-azacytidine, cytarabine, gemcitabine, 6-mercaptomurine, 6-thioguanine
- adenosine analogues such as pentostatin, cytarabine or fludarabine phosphate
- methotrexate and folinic acid
- various enzymes and compounds such as L-asparaginase, hydroxyurea, trans-retinoic acid, suramine, dexrazoxane, amifostine, herceptin as well as oestrogenic and androgenic hormones.
- It is also possible to combine a radiation treatment with the compounds of the present invention. This treatment may be administered simultaneously, separately or sequentially. The treatment will be adapted to the patient to be treated by the practitioner.
- The G-quadruplex stabilizing activity may be determined by a method using the formation of a complex with fluorescein of which the experimental protocol is described below.
- Oligonucleotides
- All the nucleotides, modified or otherwise, were synthesized by Eurogentec SA, Seraing, Belgium. The oligonucleotide FAM+DABCYL carries the catalogue reference OL-0371-0802. It has the sequence: GGGTTAGGGTTAGGGTTAGGG corresponding to 3.5 repeats of the human telomeric motif (strand rich in G). The fluorescein is attached to the 5′ end, the DABCYL to the 3′ end, by the chemical arms described by Eurogentec. The concentration of the samples is checked by spectrophotometry, recording the absorbance spectrum between 220 and 700 nm and using the molar extinction coefficient provided by the supplier.
- Buffers
- All the experiments were carried out in a 10 mM sodium cacodylate buffer pH 7.6 containing 0.1 M lithium chloride (or sodium chloride). The absence of fluorescent contamination in the buffer was checked beforehand. The fluorescent oligonucleotide is added at the final concentration of 0.2 μM.
- Study of Fluorescence
- All the measurements of fluorescence were carried out on a Spex Fluorolog DMlB apparatus, using an excitation line width of 1.8 nm and an emission line width of 4.5 nm. The samples are placed in a microquartz cuvette of 0.2×1 cm. The temperature of the sample is controlled by an external water bath. The oligonucleotide alone was analysed at 20, 30, 40, 50, 60, 70 and 80° C. The emission spectra are recorded using an excitation wavelength of 470 nm. The excitation spectra are recorded using either 515 nm or 588 nm as emission wavelength. The spectra are corrected for the response of the instrument by reference curves. A high extinction (80-90%) of the fluorescence of fluorescein at room temperature is observed, in agreement with an intramolecular folding of the oligonucleotide at 20° C. in the form of a G-quadruplex, which induces juxtaposition of its 5′ and 3′ ends which are respectively linked to fluorescein and to DABCYL. This juxtaposition causes an already-described phenomenon of extinction of fluorescence which is used for “molecular beacons”.
- Fluorescence Tm:
- An oligonucleotide stock solution at the strand concentration of 0.2 μM in 0.1 M LiCl, 10 mM cacodylate buffer, pH 7.6, is prepared beforehand, heated briefly at 90° C. and slowly cooled to 20° C., and then distributed in aliquots of 600 μl in the fluorescence cuvettes. 3 μl of water (for the control) or 3 μl of test product (stock at 200 μM, final concentration 1 μM) are then added and mixed. The samples are then allowed to incubate for at least 1 hour at 20° C. before each measurement. The use of longer incubation times (up to 24 hours) has no influence on the result obtained.
- Each experiment allows the measurement of only one sample. The latter is first incubated at an initial temperature of 20° C., heated to 80° C. over 38 minutes, left for 5 minutes at 80° C. and then cooled to 20° C. over 62 minutes. During this time, the fluorescence is measured simultaneously at two emission wavelengths (515 nm and 588 nm) using 470 nm as excitation wavelength. A measurement is carried out every 30 seconds. The temperature of the water bath is recorded in parallel, and the fluorescence profile as a function of the temperature is reconstituted from these values. The fluorescence profiles are then normalized between 20° C. and 80° C., and the temperature for which the intensity of emission at 515 nm is the mean of those at high and low temperature is called Tm. Under these conditions, the Tm of the reference sample without addition of product is 44° C. in a lithium chloride buffer. This temperature is increased to more than 55° C. in a sodium chloride buffer. The addition of a G-quadruplex-stabilizing compound induces an increase in the Tm. This increase is judged to be significant if it is greater than 30.
- The antitelomerase biological activity is determined by the following experimental protocol:
- Preparation of the Extract Enriched in Human Telomerase Activity
- The leukaemia line HL60 is obtained from ATCC (American Type Culture Collection, Rockville, USA). The cells are cultured in suspension in RPMI 1640 medium containing L-glutamine at 2 mM, penicillin 200 U/ml, streptomycin 200 μg/ml, gentamycin 50 μg/ml and supplemented with 10% heat-inactivated foetal calf serum.
- An aliquot of 105 cells is centrifuged at 3000×G and the supernatant discarded. The cell pellet is resuspended by several successive pipettings in 200 μl of lysis buffer containing 0.5% CHAPS, 10 mM Tris-HCl, pH 7.5, 1 mM MgCl2, 1 mM EGTA, 5 mM β-mercaptoethanol, 0.1 mM PMSF and 10% glycerol and is stored in ice for 30 minutes. The lysate is centrifuged at 160,000×G for 20 minutes at 4° C. and 160 μl of supernatant are recovered. The proteins in the extract are assayed by the Bradford method. The extract is stored at −80° C.
- Assay of the Telomerase Activity
- The inhibition of the telomerase activity is determined by a protocol for extension of the oligonucleotide TS (5′AATCGTTCGAGCAGAGTT3′), in the presence of a cellular extract enriched in telomerase activity and compounds which are added at various concentrations (10, 1, 0.1 and 0.01 μg/ml). The extension reaction is followed by a PCR amplification of the extension products with the aid of the oligonucleotides TS and CXext (5′GTGCCCTTACCCTTACCCTTACCCTAA3′).
- The reaction medium is prepared based on the following composition:
Tris HCl pH 8.3 20 mN MgCl2 1.5 mM Tween 20 0.005% (P/V) EGTA 1 mM dATP 50 μM dGTP 50 μM dCTP 50 μM dTTP 50 μM Oligonucleotide TS 2 μg/ml Oligonucleotide CXext 2 μg/ml Bovine serum albumin 0.1 mg/ml Taq DNA polymerase 1 U/ml alpha 32P dCTP (3000 Ci/mmol) 0.5 μl Telomerase extract 200 ng in a volume of 10 μl Test product or solvent in a volume of 5 μl Double-distilled water QS. . . 50 μl - The oligonucleotides are obtained from Eurogentec (Belgium) and are stored at −20° C. at a stock concentration of 1 mg/ml in distilled water.
- The reaction samples are assembled in 0.2 ml PCR tubes and one drop of paraffin oil is deposited on each of the reactions of the experiment before closing the tubes.
- The reaction samples are then incubated in a Cetus 4800-type PCR apparatus under the following temperature conditions:
- 15 minutes at 30° C.,
- 1 minute at 90° C.,
- followed by 30 cycles of,
- 30 seconds at 94° C.,
- 30 seconds at 50° C.,
- and 1 minute 30 seconds at 72° C.,
- followed by a final cycle of 2 minutes at 72° C.
- For each of the samples, an aliquot of 10 μl is pipetted under the oil layer and mixed with 5 μl of a loading buffer containing:
TBE 3X glycerol 32% (P/V) bromophenol blue 0.03% xylene cyanol 0.03% - The samples are then analysed by electrophoresis on 12% acrylamide gel in a 1×TBE buffer for 1 hour at a voltage of 200 volts, with the aid of a Novex electrophoresis system.
- The acrylamide gels are then dried on a sheet of whatmann 3MM paper at 80° C. for 1 hour.
- The analysis and the quantification of the reaction products are carried out with the aid of an InstantImager apparatus (Pacard).
- For each compound concentration tested, the results are expressed as percentage inhibition of the reaction and calculated from the untreated enzymatic control and from the enzyme-free sample (blank) according to the following formula:
- (compound value−blank value/enzymatic control value−blank value)×100.
- The concentration of compound inducing a 50% inhibition of the telomerase reaction (IC50) is determined with the aid of a semilogarithmic graphical representation of the inhibition values obtained as a unction of each of the compound concentrations tested.
- A compound is considered to be active as an antitelomerase agent when the quantity inhibiting 50% of the telomerase reaction is in particular less than 5 μM.
- The Cytotoxic Biological Activity on Human Tumour Lines is Determined According to the Following Experimental Protocol:
- The human cell lines KB and A549 are obtained from ATCC (American Type Culture Collection, Rockville, USA). The A549 cells are cultured in a layer in a culture flask in RPMI 1640 medium containing L-glutamine at 2 mM, penicillin 200 U/ml, streptomycin 200 μg/ml and supplemented with 10% heat-inactivated foetal calf serum. The KB cells are cultured in a layer in a culture flask in Dulbelco's medium containing L-glutamine at 2 mM, penicillin 200 U/ml, streptomycin 200 μg/ml and supplemented with 10% heat-inactivated foetal calf serum.
- The cells at the exponential growth phase are trypsinized, washed in 1× PBS and are inoculated in 96-well microplates (Costar) in an amount of 4×104 cells/ml for A549 and of 1.5×104 cells/ml (0.2 ml/well) and then incubated for 96 hours in the presence of variable concentrations of product to be studied (10, 1, 0.1 and 0.01 μg/ml, each point in quadruplicate). 16 hours before the end of the incubation, 0.02% final of neutral red is added to each well. At the end of the incubation, the cells are washed with 1× PBS and lysed with 1% sodium lauryl sulphate. The cellular incorporation of the dye, which reflects cellular growth, is evaluated by spectrophotometry at a wavelength of 540 nm for each sample with the aid of a Dynatech MR5000 reading apparatus.
- For each compound concentration tested, the results are expressed as percentage inhibition of cellular growth and calculated from the untreated control and the culture medium free of cells (blank) according to the following formula:
- (compound value−blank value/cell control value−blank value)×100.
- The concentration of compound inducing a 50% inhibition of growth (IC50) is determined with the aid of a semilogarithmic graphical representation of the inhibition values obtained as a function of each of the compound concentrations tested.
- A compound is considered to be active as cytotoxic agent if the concentration inhibiting the growth of the tumour cells tested by 50% is in particular less than 10 μM.
- The following non-limiting examples are given to illustrate the invention.
- Preparation of 2-amino-bis-4,6-[(1′-methyl-4′-amino-6′-quinaldinio)amino]triazine dichloride
- 200 cm3 of distilled water are introduced into a 2-dm3 three-necked flask and 41.6 g (0.16 mol) of 1-methyl-4,6-diaminoquinaldinium chloride hydrochloride, which may be obtained according to J. Chem. Soc., 1953, 50, are loaded, with stirring. A clear dark yellow solution is obtained into which 800 cm3 of ethanol are poured, causing an abundant precipitate. The mixture is heated to 45° C. to dissolve, and then 13.2 g (0.08 mol) of 2-amino-4,6-dichloro-triazine, which may be prepared according to J. Amer. Chem. Soc., 1945, 67, 662, are added. After a few minutes, a yellow precipitate appears, and the mixture is heated under reflux for 1 hour. The mixture is cooled and left overnight on an ice bath. The precipitate obtained is filtered and washed with four times 100 cm3 of 80% aqueous ethanol and then dried at 45° C. 47 g (100%) of 2-amino-bis-4,6-[(1′-methyl-4′-amino-6′-quinaldinio)amino]triazine dichloride monohydrochloride are thus obtained.
- Release and Purification of the Base Form
- 1.2 dm3 of distilled water and then 47 g of the monohydrochloride obtained above are added to a 2-dm3 three-necked flask, the mixture is heated to 55° C. and 30 cm3 of concentrated aqueous ammonia (d=0.925) are poured in and then the mixture is heated to 85° C. in order to promote solubilization. An insoluble matter is filtered while hot on 40 g of Supercel and washed with three times 50 cm3 of boiling water. After concentrating the filtrate to half and another filtration on 10 g of Supercel, 1.2 dm3 of ethanol are added and the mixture is stirred for 5 minutes and then allowed to stand overnight on an ice bath. In the morning, the mixture is filtered, washed with three times 50 cm3 of 66% ethanol and with twice 50 cm3 of ethanol, dried under vacuum at 45° C., and 34.2 g (79%) of crude 2-amino-bis-4,6-[(1′-methyl-4′-amino-6′-quinaldinio)amino]triazine dichloride are obtained. 600 cm3 of distilled water and the 34.2 g of crude base are introduced into a 2-dm3 three-necked flask, with stirring, the mixture is heated at 50° C. until an almost complete dissolution is obtained, and the insoluble matter is filtered. The resulting filtrate is loaded into a 3-dm3 three-necked flask, and 1.4 dm3 of ethanol are rapidly poured in, with stirring. The whitish gelatinous precipitate obtained is filtered, washed with three times 100 cm3 of ethanol, dried under vacuum at 45° C., and 30.7 g (71%) of 2-amino-bis-4,6-[(1′-methyl-4′-amino-6′-quinaldinio)amino]triazine dichloride are obtained in the form of a white solid whose characteristics are the following:
- melting point=334° C.
-
- Preparation of 2-amino-bis-4,6-[(1′-ethyl-4′-amino-6′-quinaldinio)amino]triazine dichloride
- 75 cm3 of distilled water are introduced into a 1-dm3 three-necked flask and 16.45 g (0.06 mol) of 1ethyl-4,6-diaminoquinaldinium chloride hydrochloride, which may be obtained according to U.S. Pat. No. 2,585,905, are loaded, with stirring, and then 300 cm3 of ethanol are poured in. The mixture is heated to 55° C., then 4.95 g (0.03 mol) of 2-amino-4,6-dichlorotriazine are added and the mixture is heated under reflux for 2 and a half hours. The mixture is cooled and left overnight on an ice bath. The precipitate obtained is filtered, washed with 100 cm3 of 80% ethanol and then dried at 45° C. 16.47 g (91%) of 2-amino-bis-4,6-[(1-ethyl-4′-amino-6′-quinaldinio)amino]triazine dichloride monohydrochloride are thus obtained.
- Release and Purification of the Base Form
- The 16.47 g of monohydrochloride obtained above are loaded, with stirring, into a 250-cm3 round-bottomed flask containing 200 cm3 of distilled water and 8 cm3 of concentrated aqueous ammonia (d=0.925) are poured in and the mixture is heated to reflux temperature in order to promote solubilization. A light insoluble matter is filtered while hot on Supercel and washed with twice 10 cm3 of boiling water. After concentrating the filtrate to half, 350 cm3 of ethanol are added, with stirring, causing an abundant white precipitate, and the mixture is left overnight on an ice bath. The precipitate is filtered, washed with five times 10 cm3 of 80% ethanol, dried under vacuum at 55° C., and 12.87 g (76%) of 2-amino-bis-4,6-[(1′-ethyl-4′-amino-6′-quinaldinio)amino]triazine dichloride are obtained in the form of a hygroscopic white powder whose characteristics are the following:
- melting point=302° C.
-
- Preparation of 2-dimethylamino-bis-4,6-[(1′-methyl-4′-amino-6′-quinaldinio)amino]triazine dichloride
- 60 cm3 of distilled water are introduced into a l-dm3 three-necked flask and 13.01 g (0.05 mol) of 1-methyl-4,6-diaminoquinaldinium chloride hydrochloride, which may be obtained according to J. Chem. Soc., 1953, 50, are loaded, with stirring. A yellow solution is obtained into which 240 cm3 of ethanol are poured, causing an abundant yellow precipitate. After dissolution by heating to 50° C., 4.83 g (0.025 mol) of 2-dimethylamino-4,6-dichlorotriazine, which may be prepared according to J. Amer. Chem. Soc., 1948, 70, 3726, are added. After a few minutes, a precipitate appears and the mixture is heated under reflux for 1 and a half hours. The mixture is cooled for 1 hour on an ice bath and then the precipitate obtained is filtered, washed with four times 30 cm3 of ethanol and dried. 12.92 g (86%) of 2-dimethylamino-bis-4,6-[(1′-methyl-4′-amino-6′-quinaldinio)amino]triazine dichloride are obtained in the form of a hygroscopic cream-coloured powder whose characteristics are the following:
- melting point=345° C.
-
- Preparation of 2-methylamino-bis-4,6-[(4′-amino-6′-quinaldinyl)amino]triazine trihydrochloride
- 34 cm3 of distilled water and 126 cm3 of normal hydrochloric acid are introduced into a 2-dm3 three-necked flask and 21.82 g (0.1 mol) of 4,6-diaminoquinaldine, which may be obtained according to J. Chem. Soc., 19.53, 50, are loaded, with stirring. 600 cm3 of ethanol are poured into the orange-coloured solution obtained and the mixture is heated to 65° C., and then 10.74 g (0.06 mol) of 2-methylamino-4,6-dichlorotriazine, which may be prepared according to Chem. Berichte, 1899, 32, 700, are added and 40 cm3 of ethanol are poured in. A yellow precipitate appears which thickens rapidly on heating under reflux for 2 hours. After cooling overnight on an ice bath, the precipitate obtained is filtered, washed with three times 120 cm3 of 80% ethanol, dried and 27.3 g (81%) of 2-methylamino-bis-4,6-[(4′-amino-6′-quinaldinyl)amino]-triazine trihydrochloride are obtained in the form of a hygroscopic white powder whose characteristics are the following:
- melting point=340° C.
-
- Preparation of 2-amino-bis-4,6-[(1′-methyl-6′-quinolinio)amino]triazine dichloride
- 225 cm3 of distilled water are introduced into a 2-dm3 three-necked flask and 41.5 g (0.18 mol) of 1-methyl-6-aminoquinolinium chloride hydrochloride, which may be obtained according to Zh.Org.Khim.; 1993, 29(10), 2018, are loaded, with stirring.
- A yellow solution is obtained into which 900 cm3 of ethanol are poured, causing an abundant precipitate. After dissolution by heating to 50° C., 14.8 g (0.09 mol) of 2-amino-4,6-dichlorotriazine are added, and the mixture is heated under reflux for 1 hour; a yellow precipitate appears rapidly. The mixture is cooled overnight on an ice bath and then the precipitate obtained is filtered, washed with twice 50 cm3 of ethanol, dried and 36.6 g (79%) of 2-aminobis-4,6-[(1′-methyl-6′-quinolinio)amino]triazine dichloride monohydrochloride are obtained.
- Release and Purification of the Base Form
- 200 cm3 of distilled water are added to a 1-dm3 three-necked flask and then the 36.6 g of monohydrochloride obtained above are loaded, with stirring, the mixture is heated to 80° C. and 10 cm3 of concentrated aqueous ammonia (d=0.925) are poured in, and an insoluble matter is filtered on Supercel. The preceding filtrate is poured, with stirring, over 5 minutes into a 6-dm3 three-necked flask containing 3 dm3 of ethanol, and a fine bright yellow precipitate appears, which is left for 2 days on an ice bath, then filtered, washed with twice 50 cm3 of ethanol., dried and 19.1 g (44%) of 2-amino-bis-4,6-[(1′-methyl-6′-quinolinio)amino]triazine dichloride are obtained in the form of a hygroscopic yellow powder whose characteristics are the following:
- melting point=296° C.
-
- Preparation of 2-methylamino-bis-4,6-[(4′-methylamino-6′-quinaldinyl)amino]triazine dichloride trihydrochloride
- Step A: Preparation of 4-methylamino-6-aminoquinaldine
- 240 cm3 of acetic acid are introduced into a 2-dm3 three-necked flask and 57.4 g (0.25 mol) of 6-acetamido-4-methoxyquinaldine, prepared according to J. Amer. Chem. Soc., 1948, 70, 4065, are loaded, with stirring. Methylamine is bubbled, with stirring, until saturation is obtained, and then the mixture is heated under reflux for 2 hours. The mixture is cooled, and the preceding operation is again carried out, the mixture is cooled, and the solution obtained is poured, with stirring, into a 2-dm3 three-necked flask containing 300 cm3 of distilled water and 470 cm3 of normal hydrochloric acid. The mixture is then heated at 100° C. for 11 hours and then it is left overnight on an ice bath. The crystallized product is filtered, giving 25 g of hydrochloride, the mother liquors are concentrated, left overnight on an ice bath and then filtered to give again 150 g of hydrochloride. The 175 g of hydrochloride are taken up in 300 cm3 of distilled water and dissolved by heating to 50° C., treated with 1 g of charcoal and filtered on Supercel. The filtrate is heated to 90° C. and alkalinized by addition of 54 cm3 of concentrated sodium hydroxide. The precipitate obtained by cooling overnight on an ice bath is washed with four times 100 cm3 of distilled water, dried and 33 g (70%) of 4-methylamino-6-aminoquinaldine are obtained.
- Step B
- 25 cm3 of distilled water and 1 of cm3 of normal hydrochloric acid are introduced into a 2-dm3 three-necked flask, and 18.9 g (0.101 mol) of 4-methylamino-6-aminoquinaldine are loaded, the orange-coloured solution obtained is heated to 75° C., and then 500 cm3 of ethanol are poured in over 2 minutes, and the 8.59 g (0.048 mol) of 2-methylamino-4,6-dichlorotriazine, prepared according to Example 4, are added all at once. After 5 minutes, a precipitate appears and the mixture is heated under reflux for 2 hours, allowed to cool, with stirring, for 3 hours and abandoned for 8 days on an ice bath. The precipitate obtained is filtered, washed with twice 100 cm3 of 80% ethanol and with three times 100 cm3 of ethanol, dried and 21.7 g (77%) of 2-methylamino-bis-4,6-[(4′-methylamino-6′-quinaldinyl)amino]triazine dichloride trihydrochloride are obtained in the form of a hygroscopic cream-coloured powder whose characteristics are the following:
- melting point=355° C.
-
- Preparation of 2-amino-bis-4,6-[(9′-amino-10′-methyl-2′-acridinio)amino]triazine dichloride hydrochloride
- Step A: Preparation of 2-acetamido-9-aminoacridine
- 72 cm3 of acetic acid are introduced into a 250-cm3 three-necked flask and 12 g (0.0575 mol) of 2,9-diaminoacridine, prepared according to J. Chem. Soc., 1949, 1148, are loaded, with stirring, and then 4.1 cm3 (0.0575 mol) of acetyl chloride are poured in. The temperature rises to 50° C. and the solution forms into a mass. The mixture is maintained at 60° C. for 1 hour, cooled and diluted with 200 cm3 of diethyl ether. 15.2 g of hydrochloride are obtained by filtration. 2 dm3 of distilled water are introduced into a 4-dm3 round-bottomed flask and the 15.2 g of hydrochloride are loaded, with stirring. The mixture is heated to reflux temperature, filtered and alkalinized with aqueous ammonia. The base crystallizes, is filtered and dried. 11.2 g (78%) of 2-acetamido-9-aminoacridine are obtained.
- Step B: Preparation of 2-acetamido-9-amino-10-methylacridinium sulphate
- 300 cm3 of nitrobenzene are introduced into a 1-dm3 three-necked flask and then 11.2 g (0.0446 mol) of 2-acetamido-9-aminoacridine and 11 cm3 (0.116 mol) of dimethyl sulphate are successively introduced, with stirring. The mixture is then heated at 140° C. for 20 minutes. After cooling, the precipitate obtained is filtered, washed with 20 cm3 of nitrobenzene and six times 20 cm3 of diethyl ether, air-dried and 14.35 g (85%) of 2-acetamido-9-amino-10-methylacridinium sulphate are obtained.
- Step C: Preparation of 2-acetamido-9-amino-10-methylacridinium Chloride Hydrochloride
- 600 cm3 of distilled water are introduced into a 2-dm3 round-bottomed flask and 13 g of 2-acetamido-9-amino-10-methylacridinium sulphate (0.0344 mol) are loaded, with stirring, the mixture is heated to reflux temperature until almost complete dissolution has been obtained and the insoluble matter is filtered. After cooling, 900 cm3 of a 35% aqueous sodium chloride solution are poured in, the mixture is allowed to precipitate and filtered. 20 cm3 of concentrated hydrochloric acid (d=1.18) are introduced into a 100-cm3 round-bottomed flask and the preceding compound is loaded and heated under reflux for 5 minutes, diluted with 67 cm3 of ethanol and allowed to crystallize on ice. The crystals formed are filtered, washed with twice 5 cm3 of ethanol and with three times 10 cm3 of diethyl ether, dried and 5.1 g (50%) of 2-acetamido-9-amino-10-methylacridinium chloride hydrochloride are obtained.
- Step D
- 5 cm3 of distilled water and 37 cm3 of ethanol are introduced into a 100-cm3 three-necked flask and 1 g (0.00338 mol) of 2-acetamido-9-amino-10-methylacridinium chloride hydrochloride is loaded, with stirring, and the mixture is heated to 80° C. and 0.28 g (0.0017 mol) of 2-amino-4,6-dichlorotriazine is added. After 5 minutes, a precipitate appears and the mixture is heated under reflux for 2 hours and then allowed to cool, filtered, washed with three times 3 cm3 of ethanol and with 5 cm3 of ether, dried under vacuum and 0.8 g (73%) of 2-amino-bis-4,6-[(9′-amino-10′-methyl2′-acridinio)amino]triazine dichloride hydrochloride is obtained in the form of a hygroscopic yellow ochre-coloured powder whose characteristic is the following:
- melting point=310° C.
- Preparation of 2-amino-bis-4,6-[(4′-amino-6′-quinaldinyl)amino]triazine trihydrochloride (the Corresponding Base is also Called SURFENE C)
- 5.25 dm3 of distilled water are introduced into a 10-dm3 three-necked flask and 368.4 g (2.127 mol) of 4,6-diaminoquinaldine, prepared according to Example 4, are loaded, with stirring, and then 117 g (0.709 mol) of 2-amino-4,6-dichlorotriazine, prepared according to Example 1, are added. A yellow precipitate forms immediately and the mixture is heated under reflux for 2 hours. After cooling and acidifying to pH=3.4 by addition of 1.3 dm3 of normal hydrochloric acid, the mixture is heated under reflux for 15 minutes, 20 g of charcoal are added and the reflux is maintained for 10 minutes and then the mixture is filtered. The preceding solution is introduced into a 10-dm3 three-necked flask and heated to 80° C., and then 852 cm3 of hydrochloric acid (d=1.19) are poured in over 30 minutes. At the end of the pouring, a pale yellow precipitate appears which, after cooling on an ice bath, is filtered, washed with four times 250 cm3 of a hydrochloric acid solution composed of 250 cm3 of hydrochloric acid (d=1.19) and 2 dm3 of distilled water, and then dried under vacuum at 60° C. and 385.4 g (99%) of trihydrochloride are obtained. 1.9 dm3 of ethanol are introduced into a 4-dm3 three-necked flask and the preceding 385.4 g are loaded, with stirring for 5 hours at room temperature protected from light, the mixture is filtered, then washed with twice 250 cm3 of ethanol and dried; 346 g (89%) of 2-amino-bis-4,6-[(4′-amino-6′-quinaldinyl)amino]triazine trihydrochloride are obtained in the form of a hygroscopic cream-coloured powder whose characteristic is the following:
- melting point=345° C.
- 2-Amino-bis-4,6-(p-amidinoanilino)triazine trihydrochloride
- This product may be obtained according to J. Chem. Soc., 1960, 4525, in the form of a hygroscopic cream-coloured powder.
- Preparation of 2-methylthio-bis-4,6-[(1′-methyl-4′-amino-6′-quinaldinio)amino]triazine dichloride
- 60 cm3 of distilled water are introduced into a 1-dm3 three-necked flask and 13.01 g (0.05 mol) of 1-methyl-4,6-diaminoquinaldinium chloride hydrochloride, which may be obtained according to J. Chem. Soc., 1953, 50, are loaded, with stirring. A yellow solution is obtained into which 240 cm3 of ethanol are poured, causing an abundant yellow precipitate. After dissolution by heating to 50° C., 4.90 g (0.025 mol) of 2-methylthio-4,6-dichlorotriazine, which may be prepared according to Ang. Chem. Int. Ed., 1966, 5, 960, are added. After a few minutes, a precipitate appears and the mixture is heated under reflux for one and a half hours. The mixture is cooled overnight on an ice bath, then the precipitate obtained is filtered, washed with four times 30 cM3 of ethanol and dried. 10.70 g (75%) of 2-methylthio-bis-4,6-[(1′-methyl-4′-amino-6′-quinaldinio)amino]triazine dichloride are obtained in the form of a hygroscopic cream-coloured powder whose characteristic is the following:
- melting point=320° C.
- Preparation of 2-chloro-bis-4,6-[(4′-dimethylamino-6′-quinaldinyl)amino]triazine dihydrochloride dihydrate
- Step A: Preparation of 4-dimethylamino-6-aminoquinaldine
- The procedure is carried out as in Step A of Example 6, but starting with 57.4 g (0.25 mol) of 6-acetamido-4-methoxyquinaldine, prepared according to J. Amer. Chem. Soc., 1948, 70, 4065, and 100 cm3 of a 40% aqueous dimethylamine solution in 250 cm3 of acetic acid heated at 100° C. for 2 hours in a 1-dm3 autoclave. 38.71 g (77%) of 4-dimethylamino-6-aminoquinaldine are then obtained, after acid-base purification, on carrying out the procedure as in Step A of Example 6.
- Step B
- 402 mg (2 mmol) of 4-dimethylamino-6-amino-quinaldine are dissolved in 7 cm3 of acetic acid in a 25-cm3 three-necked flask, and then 184 mg (1 mmol) of cyanuryl chloride are added over 2 minutes and then the mixture is heated at 90° C. for 3 hours. After cooling, the crystals formed are dewatered, washed with 2.5 cm3 of acetic acid and dried under vacuum at 100° C. 588 mg (94%) of 2-chloro-bis-4-,6-[(4′-dimethylamino6′-quinaldinyl)amino]triazine dihydrochloride dihydrate are thus obtained in the form of pale yellow crystals hose characteristics are the following:
- melting point=350° C.
- elemental analysis: % C=51.75 (calc=52.06); % H=5.67 (calc=5.50); % N=19.98 (calc=20.23).
- Preparation of 2-methylthio-bis-4,6-[(4′-dimethylamino-6′-quinaldinyl)amino]triazine hydrate
- Step A: Preparation of 4-dimethylamino-6-aminoquinaldine
- The procedure is carried out as in Step A of Example 6, but starting with 57.4 g (0.25 mol) of 6-acetamido-4-methoxyquinaldine, prepared according to J. Amer. Chem. Soc., 1948, 70, 4065, and 100 cm3 of a 40% aqueous dimethylamine solution in 250 cm3 of acetic acid heated at 100° C. for 2 hours in a 1-dm3 autoclave. 38.71 g (77%) of 4-dimethylamino-6-aminoquinaldine are then obtained, after acid-base purification, on carrying out the procedure as in Step A of Example 6.
- Step B
- 100 cm3 of 90% aqueous ethanol are introduced into a 250-cm3 three-necked flask and 4.02 g (0.02 mol) of 4-dimethylamino-6-aminoquinaldine and 1.96 g (0.01 mol) of. 2-methylthio-4,6-dichlorotriazine, which may be prepared according to Ang. Chem. Int. Ed., 1966, 5, 960, are loaded, with stirring. After a few minutes, a precipitate appears and the mixture is heated under reflux for 1 and a half hours. The mixture is cooled overnight on an ice bath and then the precipitate obtained is filtered and washed with four times 30 cm3 of ethanol and dried. 5.26 g (88%) of crude hydrochloride are obtained.
- 75 cm3 of 90% aqueous ethanol are added to a 250-cm3 three-necked flask and then the 5.26 g of hydrochloride previously obtained are loaded, with stirring, the mixture is heated to 80° C. and 5 cm3 of concentrated aqueous ammonia (d=0.925) are poured in, and the mixture is allowed to crystallize for 2 days on an ice bath. The mixture is filtered, washed with twice 5 cm3 of 90% aqueous ethanol, dried and 3.20 g (59.5%) of 2-methylthio-bis-4,6-[(4′-dimethylamino-6′-quinaldinyl)amino]triazine hydrate are obtained in the form of a pale yellow solid whose characteristics are the following:
- melting point=280-3° C.
- elemental analysis: % C=62.06 (calc=62.48); % H=5.81 (calc=62.48); % N=23.80 (calc=23.42).
- Preparat ion of N,N′-(4-amino-6-quinaldinyl)urea dihydrochloride (the corresponding base, also called SURFENE, may be prepared according to Ang. Chem 1939, 891)
- 400 cm3 of distilled water are introduced into a 500-cm3 three-necked flask and 30 g (0.2 mol) of 4,6-diaminoquinaldine, which may be prepared according to J. Chem. Soc., 1953, 50, are™ loaded, with stirring, and then 8.4 g (0.06 mol) of sodium acetate trihydrate are added and the mixture is heated to 95-96° C. A stream of phosgene is then caused to pass through until saturation is obtained (5 to 10 minutes), and then the mixture is maintained at 95-96° C. for 1 hour. After cooling and acidifying by addition of 200 cm3 of 6 N hydrochloric acid, the precipitate formed is dewatered, washed with 200 cm 3 of N hydrochloric acid and dried under vacuum at 60°, and 30 g of crude hydrochloride are thus obtained, which hydrochloride is recrystallized from 300 cm3 of distilled water and 30 cm3 of concentrated hydrochloric acid in the presence of charcoal. After cooling, the crystals formed are dewatered, washed with N hydrochloric acid, and then with acetone and dried under vacuum at 40° C. 27 g (60.5%) of N,N′-(4-amino-6-quinaldinyl)urea dihydrochloride are thus obtained in the form of a hygroscopic cream-coloured powder whose characteristic is the following:
- melting point=329-40° C.
- Preparation of N1,N5-bis (7-chloro-1-methyl4-quinolinio)pentane-1,5-diamine diiodide
- 3 g (7 mmol) of N1,N5-bis(7-chloroquinolin-4-yl)pentane-1, 5-diamine, which may be prepared according to J. Med. Chem. 1992, 35, 2129, are dissolved, by heating to around 50° C., in 60 cm3 of butan-2-one. 3 g (21 mmol) of methyl iodide are added and the mixture is heated under reflux for 5 hours. The crystals formed are dewatered, washed with butan-2-one and then with diethyl ether and dried under vacuum. 3 g (60%) of N1,N5-bis(7-chloro-l-methyl-4-quinolinio)pentane-1,5-diamine diiodide are thus obtained in the form of beige crystals whose characteristic is the following:
- melting point=277-78° C.
- Preparation of bis-2,4-[(4′-amino-6′-quinaldinyl)amino]pyrimidine trihydrochloride pentahydrate
- 1.73 g (10 mmol) of 4,6-diamino-1-methylquinoline, which may be obtained according to J. Chem. Soc., 1953, 50, and 0.74 g of 2,4-dichloropyrimidine in 75 cm3 of ethanol and 5 cm3 of water are heated for 5 hours under reflux in a 250-cm3 three-necked flask. The reaction medium is concentrated by half and then allowed to crystallize on an ice bath overnight. The precipitate formed is dewatered, washed with ethanol and then with diethyl ether and dried under vacuum. The precipitate obtained is stirred for 6 hours in 10 cm3 of 0.2 N hydrochloric acid and then dewatered, washed with water and dried under vacuum at 80° C. 0.98 g (46.5%) of bis-2,4-[(4′-amino6′-quinaldinyl)amino]pyrimidine trihydrochloride pentahydrate is thus obtained in the form of a yellow solid whose characteristics are the following:
- melting point=310-20° C.
- elemental analysis: % C=47.37 (calc=47.46); % H=5.51 (calc=5.67); % N=18.41 (calc=18.45); % Cl=15.84 (calc=15.76)
- Preparation of 1,5-(4′-amino-6′-quinaldinyl)-biguanide trihydrochloride dihydrate
- 5 cm3 of water, 3 cm3 of 5N hydrochloric acid, 1.3 g (7.5 mmol) of 4,6-diaminoquinaldine, which may be obtained according to J. Chem. Soc., 1953, 50, and 0.34 g (3.75 mmol) of sodium dicyanamide are added to a 25-cm3 three-necked flask and the mixture is heated at 50-55° C. overnight. After cooling, the precipitate formed is dewatered, washed with ice-cold water and dried under vacuum at 70° C. 0.47 g (22.5%) of 1,5-(4′-amino-6′-quinaldinyl)biguanide trihydrochloride dihydrate is thus obtained in the form of yellow crystals whose characteristics are the following:
- melting point=262-66° C.
- elemental analysis: % C=47.85 (calc=47.56); % H=5.67 (calc=5.38); % N=22.96 (calc=22.69); % Cl=18.79 (calc=19.14).
- The G-quartet, antitelomerase and cytotoxic activities of the various compounds exemplified are determined according to the operating protocols described above.
FLUORESCENCE TRAP Cytotox. A549 EXAMPLE Tm (° C.) IC50 (μM) IC50 (μM) 1 — 0.25 0.59/1.9* 2 48° 0.056 4.7 3 52° 0.22 — 4 48° 0.51 3.1 5 57° 0.13 0.56/1.8* 6 44° 0.3 1.9 7 55° 0.89 4.9 8 — 0.051 9.1 9 — 0.74 0.53 10 — 0.24 3.6 11 57° 3 5.14 12 70° 0.041 0.44/1.1* 13 — 0.72 — 14 — 1.4/4.9* 6.5 15 53° 0.49 8.7 16 52° 2/4.5* 5.8 -
G4 Cytotox. Tm TRAP A549 A Ar1 R3 Ar2 R′3 ° C. IC50 μM IC50 μM 17-1 SMe H H 57 0.049 1.6 17-2 SMe H H 0.95 6.1 17-3 SMe H H 3.9 3.2 18-1 SMe H Me 47 3.5 18-2 SMe H H 49 2.3 18-3 SMe H H 57 0.34 10 18-4 SMe H H 50 2.2 18-5 SMe H H 47 3.4 18-6 SMe H H 50 2.6 10 18-7 SMe H H 51 3.3 8 18-8 SMe H H 49 3.4 18-9 SMe H H 51 3.4 9.5 18-10 SMe H H 49 3.3 10 18-11 SMe H H 48 3.3 1.3 18-12 SMe H H 2.8 18-13 SMe H H 3.4 19-1 N(Et)2 H H 58 1.0 1.5 19-2 N(Et)2 H H 53 2.5
Claims (21)
1. Compounds which bind the G-quadruplex structure of telomers, characterized in that they correspond to the following general formula:
nitrogen-containing aromatic ring-NR3-distribution agent-NR′3-aromatic ring
in which
the nitrogen-containing aromatic ring represents:
a quinoline optionally substituted with at least one group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen or a short-chain C1-C4 alkyl and/or alkoxy radical and/or
a quinoline possessing a nitrogen atom in quaternary form or
a benzamidine or
a pyridine
the aromatic ring represents
a quinoline optionally substituted with at least one group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen or a short-chain C1-C4 alkyl and/or alkoxy radical and/or
a quinoline possessing a nitrogen atom in quaternary form or
a benzamidine or
a pyridine or
a phenyl ring optionally substituted at the meta or para position with a halogen group, C1-C4 alkoxy group, cyano group, carbonylamino group optionally substituted with one or more C1-C4 alkyl groups, guanyl groups, C1-C4 alkylthio groups, amino groups, C1-C4 alkylamino groups, C1-C4 dialkylamino groups for each alkyl group, nitro group, alkyleneamino group or alkenyleneamino group or
a mono- or bi- or tricyclic heterocyclic ring comprising 0 to 2 heteroatoms per ring provided that at least one heteroatom is present in at least one ring optionally substituted with one or more C1-C4 alkyl groups or with alkylene or alkenylene groups
R3 and R′3, which are identical or different, represent independently of one another hydrogen or a C1-C4 alkyl radical
the distribution agent represents:
a triazine group optionally substituted with an alkyl radical having 1 to 4 carbon atoms, a thio, oxy or amino radical which are themselves optionally substituted with one or more short-chain alkyl chains containing 1 to 4 carbon atoms or a halogen atom or
a carbonyl group or
a group C(═NH)—NH—C(═NH) or
an alkyldiyl group containing 3 to 7 carbon atoms or
a diazine group optionally substituted with the same groups as the triazine or one of its salts.
2. Compounds according to claim 1 , characterized in that the distribution agent is chosen from the triazine or diazine groups.
3. Compounds according to claim 2 , characterized in that the diazine groups are pyrimidines.
4. Compounds according to claim 1 , characterized in that they correspond to formula (I) below:
in which:
A represents
an amino group of formula NR1R2 in which R1 and R2, which are identical or different, represent hydrogen or a straight or branched alkyl group containing 1 to 4 carbon atoms or
a group OR1 or SR1 in which R1 has the same meaning as above or
an alkyl group containing 1 to 4 carbon atoms or a trifluoromethyl group or
a hydrogen atom or
a halogen atom chosen from fluorine, chlorine, bromine or iodine
R3 and R′3, which are identical or different, represent independently of one another hydrogen or a C1-C4 alkyl group
Ar1 and Ar2, which are identical or different, represent
1. when Ar1 and Ar2 are identical:
a quinoline motif optionally substituted with at least one group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen or a short-chain alkyl and/or alkoxy radical containing 1 to 4 carbon atoms or
a quinoline possessing a nitrogen atom in quaternary form or
a benzamidine or
a pyridine attached at the 4-position or fused with an aryl or heteroaryl group optionally substituted with a C1-C4 alkyl group
2. when Ar1 and Ar2 are different
Ar1 and Ar2 both represent one of the possibilities mentioned above for Ar1 and Ar2 or
Ar1 represents one of the above possibilities and Ar2 represents
a phenyl ring optionally substituted at the meta or para position with a halogen group, C1-C4 alkoxy group, cyano group, carbonylamino group optionally substituted with one or more C1-C4 alkyl groups, guanyl groups, C1-C4 alkylthio groups, amino groups, C1-C4 alkylamino groups, C1-C4 dialkylamino groups for each alkyl group, nitro group, alkyleneamino group or alkenyleneamino group
a mono- or bi- or tricyclic heterocyclic ring comprising 0 to 2 heteroatoms per ring provided that at least one heteroatom is present in at least one ring optionally substituted with one or more C1-C4 alkyl groups or with alkylene or alkenylene groups or one of its salts.
5. Compounds according to claim 3 , characterized in that Ar1 and Ar2 represent a group chosen from the following groups: 4-amino- or 4-methylamino- or 4-dimethylamino-quinolyl or -quinolinium in which the quinolinium ring is optionally substituted with a methyl group.
6. Compounds according to claim 1 , characterized in that the groups R1 and R2 represent the methylthio, amino, alkylamino or dialkylamino radical, in which radicals the alkyl groups possess 1 to 4 carbon atoms.
7. Compounds according to claim 2 , characterized in that A represents a methylthio group.
8. Compounds of claim 1 , characterized in that they have a telomerase-inhibiting activity.
9. Compounds according to any one of the preceding claims, characterized in that they have an anticancer activity.
10. Novel compounds corresponding to the following formula (I):
in which:
A represents
an amino group of formula NR1R2 in which R1 and R2, which are identical or different, represent a straight or branched alkyl group containing 1 to 4 carbon atoms or
a group OR1 or SR1 in which R1 represents hydrogen or has the same meaning as above or
an alkyl group containing 1 to 4 carbon atoms or a trifluoromethyl group or
a hydrogen atom or
a halogen atom chosen from fluorine, chlorine, bromine or iodine
R3 and R′3, which are identical or different, represent independently of one another a hydrogen atom or a C1-C4 alkyl group
Ar1 and Ar2, which are identical or different, represent
1. when Ar1 and Ar2 are identical:
a quinoline motif optionally substituted with at least one group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen or a short-chain alkyl and/or alkoxy radical containing 1 to 4 carbon atoms and/or
a quinoline possessing a nitrogen atom in quaternary form or
a benzamidine except in the case where A represents diethylamine, hydrogen or an amine group
a pyridine attached at the 4-position or fused with an aryl or heteroaryl group optionally substituted with a C1-C4 alkyl group
2. when Ar1 and Ar2 are different
Ar1 and Ar2 both represent one of the possibilities mentioned above for Ar1 and Ar2 or
Ar1 represents one of the above possibilities and Ar2 represents
a phenyl ring optionally substituted at the meta or para position with a halogen group, C1-C4 alkoxy group, cyano group, carbonylamino group optionally substituted with one or more C1-C4 alkyl groups, guanyl groups, C1-C4 alkylthio groups, amino groups, C1-C4 alkylamino groups, C1-C4 dialkylamino groups for each alkyl group, nitro group, alkyleneamino group or alkenyleneamino group
a mono- or bi- or tricyclic heterocyclic ring comprising 0 to 2 heteroatoms per ring provided that at least one heteroatom is present in at least one ring optionally substituted with one or more C1-C4 alkyl groups or with alkylene or alkenylene groups
or one of its salts excluding 2-amino-bis-4,6-[(4′-amino-6′-quinaldinyl)amino]triazine dihydrochloride and 2-amino-bis-4,6-(p-amidinoanilino)triazine dihydrochloride.
11. Compounds according to claim 10 , characterized in that when Ar1 and Ar2 are identical, Ar1 and Ar2 represent a group chosen from 4-amino- or 4-methylamino- or 4-dimethylamino-quinolyl or -quinolinium groups in which the quinolinium ring is optionally substituted with a methyl group.
12. Compounds according to claim 10 , characterized in that R1 and R2 represent hydrogen.
13. Compounds according to claim 10 , characterized in that A represents a methylthio group.
14. Compounds according to claim 10 , characterized in that when Arl and Ar2 are different
1. Ar1 represents:
a quinoline motif substituted with at least one group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen or a short-chain alkyl or alkoxy radical containing 1 to 4 carbon atoms and/or
a quinoline possessing a nitrogen atom in quaternary form or
a benzamidine except in the case where A represents diethylamine, hydrogen or an amine group or
a pyridine attached at the 4-position or fused with an aryl or heteroaryl group
2. Ar2 represents
a ring as defined above but different or
a phenyl ring optionally substituted at the meta or para position with a halogen, methoxy, cyano, carbonylamino, guanyl, methylthio, amino, methylamino, dimethylamino, morpholine, alkyleneamino or alkenyleneamino group
a quinoline, benzimidazole, indole, benzothiophene, benzofuran, benzothiazol, benzoxazol, carbazol, quinazoline or quinoxaline ring optionally substituted with one or more C1-C4 alkyl groups or with alkylene or alkenylene groups
or one of its salts excluding 2-amino-bis-4,6-[(4′-amino-6′-quinaldinyl)amino]triazine dihydro-chloride and 2-amino-bis-4,6-(p-amidinoanilino)-triazine.
15. Compounds according to claim 10 chosen from:
2-amino-bis-4,6-[(1′-methyl-4′-amino-6′-quinaldinio)amino]triazine dichloride
2-amino-bis-4,6-[(1′-ethyl-4′-amino-6′-quinaldinio)amino]triazine dichloride
2-dimethylamino-bis-4,6-[(1′-methyl4′-amino-6′-quinaldinio)amino]triazine dichloride
2-methylamino-bis-4,6-[(4′-amino-6′-quinaldinyl)amino]triazine trihydrochloride
2-amino-bis-4,6-[(1′-methyl-6′-quinolinio)amino]triazine dichloride
2-methylamino-bis-4,6-[(4′-methylamino-6′-quinaldinyl)amino]triazine dichloride trihydrochloride
2-amino-bis-4,6-[(9′-amino-10′-methyl-2′-acridinio)amino]triazine dichloride hydrochloride
2-methylthio-bis-4,6-[(1′-methyl-4′-amino-6′-quinaldinio)amino]triazine dichloride
2-chloro-bis-4,6-[(4′-dimethylamino-6′-quinaldinyl)amino]triazine dihydrochloride dihydrate
2-methylthio-bis-4,6-[(4′-dimethylamino-6′-quinaldinyl)amino]triazine hydrate
N,N′-(4-amino-6-quinaldinyl)urea dihydrochloride
N1,N5-bis(7-chloro-l-methyl-4-quinolinio)pentane-1,5-diamine diiodide
bis-2,4-[(4′-amino-6′-quinaldinyl)amino]-pyrimidine trihydrochloride pentahydrate
1,5-(4′-amino-6′-quinaldinyl)biguanide trihydrochloride dihydrate.
16. Compounds according to claim 15 chosen from:
2-methylthio-bis-4,6-[(4′-dimethylamino-6′-quinaldinyl)amino]triazine hydrate
2-chloro-bis-4,6-[(4′-dimethylamino-6′-quinaldinyl)amino]triazine dihydrochloride dihydrate
6-[4-(4-amino-2-methylquinolin-6-ylamino)-6-methylsulphanyl-[13,5]triazin-2-ylamino]-2-methyl quinolin-4-ol
N6-[4-(4-dimethylamino-2-methylquinolin-6-ylamino)-6-methylsulphanyl-[1,3,5]triazin-2-yl]-2-methylquinoline-4,6-diamine
N6-[4-(4-amino-2-methylquinolin-6-ylamino)-6-methylsulphanyl-[1,3,5]triazin-2-yl]-2-methylquinoline-4,6-diamine
N6-[4-(4-methoxy-2-methylquinolin-6-ylamino)-6-methylsulphanyl-[1,3,5]triazin-2-yl]-4-methoxy-2-methylquinolin-6-amine.
17. Use of the compounds of claim 10 as pharmaceutical product for human use.
18. Therapeutic combinations consisting of a compound according to claim 1 and of another anticancer compound.
19. Combinations according to claim 18 , characterized in that the anticancer compound is chosen from alkylating agents, platinum derivatives, antibiotic agents, antimicrotubule agents, anthracyclines, group I and II topoisomerases, fluoropyrimidines, cytidine analogues, adenosine analogues, various enzymes and compounds such as L-asparaginase, hydroxyurea, trans-retinoic acid, suramine, irinotecan, topotecan, dexrazoxane, amifostine, herceptin as well as oestrogenic and androgenic hormones.
20. Therapeutic combination consisting of a compound according to claim 1 and of radiation.
21. Combinations according to any one of claims 18 to 20 , characterized in that each of the compounds or treatments is administered simultaneously, separately or sequentially.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/658,394 US20040053966A1 (en) | 1999-11-29 | 2003-09-10 | Chemical derivatives and their application as antitelomerase agent |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9915031 | 1999-11-29 | ||
FR9915031A FR2801588B1 (en) | 1999-11-29 | 1999-11-29 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENT |
US17663200P | 2000-01-19 | 2000-01-19 | |
US21805900P | 2000-07-13 | 2000-07-13 | |
FR0010561 | 2000-08-11 | ||
FR0010561 | 2000-08-11 | ||
US09/722,361 US6645964B1 (en) | 1999-11-29 | 2000-11-28 | Chemical derivatives and their application as antitelomerase agent |
US10/658,394 US20040053966A1 (en) | 1999-11-29 | 2003-09-10 | Chemical derivatives and their application as antitelomerase agent |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/722,361 Division US6645964B1 (en) | 1999-11-29 | 2000-11-28 | Chemical derivatives and their application as antitelomerase agent |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040053966A1 true US20040053966A1 (en) | 2004-03-18 |
Family
ID=29408093
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/722,361 Expired - Fee Related US6645964B1 (en) | 1999-11-29 | 2000-11-28 | Chemical derivatives and their application as antitelomerase agent |
US10/658,394 Abandoned US20040053966A1 (en) | 1999-11-29 | 2003-09-10 | Chemical derivatives and their application as antitelomerase agent |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/722,361 Expired - Fee Related US6645964B1 (en) | 1999-11-29 | 2000-11-28 | Chemical derivatives and their application as antitelomerase agent |
Country Status (1)
Country | Link |
---|---|
US (2) | US6645964B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050070571A1 (en) * | 2001-03-23 | 2005-03-31 | Aventis Pharma S.A. | Chemical derivatives and their application as antitelomerase agents |
US20070232572A1 (en) * | 2003-02-07 | 2007-10-04 | Aventis Pharma S.A. | Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent |
US7332489B2 (en) | 2002-09-23 | 2008-02-19 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7163943B2 (en) | 2001-09-21 | 2007-01-16 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
US7132423B2 (en) * | 2001-09-21 | 2006-11-07 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
US7112587B2 (en) * | 2001-09-21 | 2006-09-26 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
US7169785B2 (en) * | 2001-09-21 | 2007-01-30 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
US7335770B2 (en) * | 2004-03-24 | 2008-02-26 | Reddy U5 Therapeutics, Inc. | Triazine compounds and their analogs, compositions, and methods |
JP2008540585A (en) * | 2005-05-19 | 2008-11-20 | プロメティック・バイオサイエンスィズ・インコーポレーテッド | Compounds for treating metastatic melanoma and other cancers, compositions containing such compounds, and methods of treatment |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5767278A (en) * | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
US5770613A (en) * | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
US5854244A (en) * | 1992-03-27 | 1998-12-29 | Cancer Research Campaign Technology Limited | Melamine derivatives for use in the treatment of cancer |
US5863936A (en) * | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
US6150360A (en) * | 1998-03-27 | 2000-11-21 | Janssen Pharmaceutica N.V. | Trisubstituted 1,3,5-Triazine Derivatives |
US6262053B1 (en) * | 1999-06-23 | 2001-07-17 | Parker Hughes Institute | Melamine derivatives as potent anti-cancer agents |
US6362210B1 (en) * | 1999-07-27 | 2002-03-26 | Boehringer Ingelheim Pharma Kg | Carboxylic acid amides, pharmaceutical compositions containing these compounds and their use |
US20030013711A1 (en) * | 2001-02-23 | 2003-01-16 | Patrick Mailliet | Chemical derivatives and their application as antitelomerase agents |
US6858608B2 (en) * | 2001-01-09 | 2005-02-22 | Aventis Pharma S.A. | Chemical derivatives and their application as antitelomerase agents |
US20050070571A1 (en) * | 2001-03-23 | 2005-03-31 | Aventis Pharma S.A. | Chemical derivatives and their application as antitelomerase agents |
US6995175B2 (en) * | 2001-05-28 | 2006-02-07 | Aventis Pharma S.A. | Chemical derivatives and their application as antitelomerase agent |
-
2000
- 2000-11-28 US US09/722,361 patent/US6645964B1/en not_active Expired - Fee Related
-
2003
- 2003-09-10 US US10/658,394 patent/US20040053966A1/en not_active Abandoned
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5854244A (en) * | 1992-03-27 | 1998-12-29 | Cancer Research Campaign Technology Limited | Melamine derivatives for use in the treatment of cancer |
US5863936A (en) * | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
US5770613A (en) * | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
US5767278A (en) * | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
US6150360A (en) * | 1998-03-27 | 2000-11-21 | Janssen Pharmaceutica N.V. | Trisubstituted 1,3,5-Triazine Derivatives |
US6262053B1 (en) * | 1999-06-23 | 2001-07-17 | Parker Hughes Institute | Melamine derivatives as potent anti-cancer agents |
US6362210B1 (en) * | 1999-07-27 | 2002-03-26 | Boehringer Ingelheim Pharma Kg | Carboxylic acid amides, pharmaceutical compositions containing these compounds and their use |
US6858608B2 (en) * | 2001-01-09 | 2005-02-22 | Aventis Pharma S.A. | Chemical derivatives and their application as antitelomerase agents |
US7179816B2 (en) * | 2001-01-09 | 2007-02-20 | Aventis Pharma S.A. | Chemical derivatives and their application as antitelomerase agents |
US20030013711A1 (en) * | 2001-02-23 | 2003-01-16 | Patrick Mailliet | Chemical derivatives and their application as antitelomerase agents |
US20050070571A1 (en) * | 2001-03-23 | 2005-03-31 | Aventis Pharma S.A. | Chemical derivatives and their application as antitelomerase agents |
US6887873B2 (en) * | 2001-03-23 | 2005-05-03 | Aventis Pharma S.A. | Triazine derivatives and their application as antitelomerase agents |
US6995175B2 (en) * | 2001-05-28 | 2006-02-07 | Aventis Pharma S.A. | Chemical derivatives and their application as antitelomerase agent |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050070571A1 (en) * | 2001-03-23 | 2005-03-31 | Aventis Pharma S.A. | Chemical derivatives and their application as antitelomerase agents |
US7482352B2 (en) | 2001-03-23 | 2009-01-27 | Aventis Pharma S.A. | Chemical derivatives and their application as antitelomerase agents |
US20090226411A1 (en) * | 2001-03-23 | 2009-09-10 | Aventis Pharma S.A. | Chemical derivatives and their application as antitelomerase agents |
US7332489B2 (en) | 2002-09-23 | 2008-02-19 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
US20070232572A1 (en) * | 2003-02-07 | 2007-10-04 | Aventis Pharma S.A. | Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent |
Also Published As
Publication number | Publication date |
---|---|
US6645964B1 (en) | 2003-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2179001A (en) | Arylamine derivatives and their use as anti-telomerase agent | |
US20060199840A1 (en) | Chemical derivatives and their application as antitelomerase agent | |
US20090226411A1 (en) | Chemical derivatives and their application as antitelomerase agents | |
US6645964B1 (en) | Chemical derivatives and their application as antitelomerase agent | |
AU2002251140B2 (en) | Chemical derivatives and their use as anti-telomerase agent | |
US7179816B2 (en) | Chemical derivatives and their application as antitelomerase agents | |
JP2009511548A (en) | Novel pyrimidine-2,4-diamine derivatives and their use as modulators of calcium-dependent potassium channels of small conductance | |
AU2002229859B2 (en) | Chemical derivatives and their use as anti-telomerase agent | |
US20030013711A1 (en) | Chemical derivatives and their application as antitelomerase agents | |
US20070232572A1 (en) | Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent | |
US20020103169A1 (en) | Chemical derivatives and use thereof as antitelomerase agents | |
US20040192686A1 (en) | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | |
FR2801588A1 (en) | Diarylamino diazine and triazine derivatives are telomerase inhibitors and G-quadruplex stabilizers, useful in the treatment of cancers | |
FR2822468A1 (en) | New arylamino-substituted triazine or diazine derivatives, used as telomerase inhibiting anticancer agents, by fixing the G-quadruplex structure of DNA or RNA | |
FR2825090A1 (en) | New compounds as telomerase inhibitors that fix the G-quadruplex structure of DNA or RNA, useful in the treatment of cancers | |
FR2821355A1 (en) | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |